

Citation: Zhang X-E, Pang Y-b, Bo Q, Hu S-Y, Xiang J-Y, Yang Z-R, et al. (2023) Protective effect of paeoniflorin in diabetic nephropathy: A preclinical systematic review revealing the mechanism of action. PLoS ONE 18(9): e0282275. https://doi.org/10.1371/journal.pone.0282275

Editor: Chun-Hua Wang, Foshan University, CHINA

Received: November 22, 2022

Accepted: February 10, 2023

Published: September 21, 2023

Copyright: © 2023 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: Funding this article was supported by the National Natural Science Foundation of China (grant number No. 8207152547), Department of science and technology of Sichuan Province, P.R (grant number No.2021ZYD0089), "Youth Qi Huang Scholar" by State Administration of TCM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

RESEARCH ARTICLE

Protective effect of paeoniflorin in diabetic nephropathy: A preclinical systematic review revealing the mechanism of action

Xue-Er Zhang¹°, Yao-bin Pang¹°, Qu Bo²°, Shuang-Yuan Hu³°, Ju-Yi Xiang³°, Zheng-Ru Yang¹°, Xiao-Mei Zhang⁴°, An-Jing Chen¹°, Jin-Hao Zeng³°*, Xiao Ma⁵°*, Jing Guo ¹°*

1 Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China, 2 Department of Nephropathy, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China, 3 TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China, 4 Institute of Medicinal Chemistry of Chinese Medicine, Chongqing Academy of Chinese Materia Medica, Chongqing, China, 5 State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China

• These authors contributed equally to this work.

* guojing66@cdutcm.edu.cn (JG); zengjinghao@cdutcm.edu.cn (JHZ); tobymaxiao@cdutcm.edu.cn (XM)

Abstract

Background

Paeoniflorin (PF), the main active glucoside of Paeonia Lactiflora, has many pharmacological activities, such as inhibition of vasodilation, hypoglycemia, and immunomodulation. Although the current evidence has suggested the therapeutic effects of PF on diabetic nephropathy (DN), its potential mechanism of action is still unclear.

Purpose

A systematic review and meta-analysis of the existing literature on paeoniflorin treatment in DN animal models was performed to evaluate the efficacy and mechanism of PF in DN animal models.

Methods

The risk of bias in each study was judged using the CAMARADES 10-item quality checklist with the number of criteria met varying from 4 / 10 to 7 / 10, with an average of 5.44. From inception to July 2022, We searched eight databases. We used the Cochrane Collaboration's 10-item checklist and RevMan 5.3 software to assess the risk of bias and analyze the data. Three-dimensional dose/time-effect analyses were conducted to examine the dosage/ time-response relations between PF and DN.

Results

Nine animal studies were systematically reviewed to evaluate the effectiveness of PF in improving animal models of DN. Meta-analysis data and intergroup comparisons indicated

Competing interests: All authors declare no conflicts of interest.

Abbreviations: AUC, area under the curve; Bax and Bcl-2. BCL2-associated X and B-cell lymphoma-2: BG, blood glucose; CVD, cardiovascular disease; CI, confidence interval; CP-25, paeoniflorin-6'-obenzene sulfonate; Chol, cholesterol; CD68, cluster of differentiation 68; DN, diabetic nephropathy; DKD, diabetic kidney disease; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; ESRD. end-stage renal disease; FBG, fasting bloodglucose; FIN, fasting insulin level; GSH-Px, glutathione peroxidase; GRK2, G protein coupled receptor kinases 2; GFR, glomerular filtration rate; HOMA-IR, homeostasis model assessment; iNOS, inducible nitric oxide synthase: ICAM1. intercellular cell adhesion molecule 1; INR, international normalized ratio; MCP-1, monocyte chemoattractant protein 1; KW / BW ratio, kidney weight / body weight; IL-1β, interleukin 1β; MyD88, myeloid differentiation factor 88; MD, mean difference: NF-kB-p65, nuclear factor kappa p65; NF-kBp-p65, nuclear factor kappa p-p65; Nrf2, nuclear factor erythroid-2 related factor 2; P-irs1, phosphorylated-insulin receptor substrate 1; PF, Paeoniflorin; P-JAK2, phosphorylated-Janus kinase 2; P-IRAK1, phosho-interleukin-1 receptorassociated kinase: P-IRF3. phosphorylated interferon regulatory factor 3; P-STAT3, phosphorylated signal transducer and activator of transcription 3; SOD, superoxide dismutase; SMD, standardized mean difference; SIRT1, silent mating type information regulation 2 homolog 1; SD, Sprague Dawley; SCR, serum creatinine; STZ, streptozotocin; TGP, total glucoside of peony; TLR2, toll like receptors 2; TGF_{β1}, transforming growth factor-\beta1; TG, triglyceride; TLR4, toll like receptors 4; TNF-a, tumor necrosis factor-a; TRIF, TIR domain-containing adaptor inducing interferon-B: UAIb/UCR. urinary albumin/urinary creatinine; 24-h urinary protein, 24-hour urinary protein excretion rate.

that PF slowed the index of mesangial expansion and tubulointerstitial injury, 24-h urinary protein excretion rate, expression of anti-inflammatory mediators (mRNA of MCP-1, TNF- α , iNOS, and IL-1 β), and expression of immune downstream factors (P-IRAK1, TIRF, P-IRF3, MyD88, and NF- κ Bp-p65). Furthermore, modeling methods, animal species, treatment duration, thickness of tissue sections during the experiment, and experimental procedures were subjected to subgroup analyses.

Conclusion

The present study demonstrated that the reno-protective effects of PF were associated with its inhibition on macrophage infiltration, reduction of inflammatory mediators, and immunomodulatory effects. In conclusion, PF can effectively slow down the progression of DN and hold promise as a protective drug for the treatment of DN. Due to the low bioavailability of PF, further studies on renal histology in animals are urgently needed. We therefore recommend an active exploration of the dose and therapeutic time frame of PF in the clinic and in animals. Moreover, it is suggested to actively explore methods to improve the bioavailability of PF to expand the application of PF in the clinic.

1. Introduction

Diabetic nephropathy (DN) is a leading cause of end-stage renal disease (ESRD). DN occurs in approximately 30% of patients with type 1 diabetes mellitus (T1DM) and approximately 40% of patients with type 2 diabetes mellitus (T2DM), representing a diabetic microvascular complication caused by glomerulopathy and tubulopathy [1, 2]. The typical presenting features of DN are early hyperfiltration and albuminuria (glomerular filtration rate (GFR) below 60 ml/ min /1.73m² or albumin-to-creatinine ratio (ACR) higher than 30 mg / g for more than 3 months) and then the gradual decline of renal function [3]. The pathogenesis of DN is complex and diverse, mainly involving changes in renal hemodynamics and renal structure (characterized by glomerular hypertrophy, inflammation, and fibrosis). Moreover, DN is closely related to the dysfunction of the angiotensin aldosterone system and immune system. Studies have shown that the intrarenal inflammation mediated by macrophage activation and toll-like receptors (TLRs) plays an important role in the development and progression of DN [4]. Silent information regulator 1 (SIRT1) / nuclear factor related factor 2 (Nrf2) / nuclear factor-κB $(NF-\kappa B)$ signaling pathways are closely related to inflammation and oxidative stress [5]. Hence, the SIRT1/Nrf2/NF-κB signal may become a potential therapeutic target to inhibit oxidative stress and inflammation, thereby exerting reno-protective effects in DN.At present, few few therapeutic agents directly target the renal and vascular complications of diabetes, and most studies focus on albuminuria. However, the association between albuminuria and renal function decline may not be significant, because clinically, some diabetic patients with renal insufficiency still show albuminuria in the normal range [6]. The prevalence of normoalbuminuric diabetes mellitus (DADN) with renal dysfunction is gradually increasing and has become the prevalent phenotype of DN [7]. Therefore, it is necessary to seek novel downstream bioindicators and effective treatments to delay DN progression.

Paeoniflorin (PF) is the most abundant component (> 40%) of the total glucoside of peony (TGP), and also the main bioactive component. The plant extract TGP is a mixture of glycosides isolated from the roots of the traditional herb Paeonia Lactiflora Pall [8]. Mechanistically, PF can regulate the function of immune cells and endothelial cells (ECS), reduce the production of inflammatory mediators, and restore abnormal signal transduction [9]. PF has shown notable efficacy in treating rheumatoid arthritis, psoriasis, systemic lupus erythematosus, and diabetes [10–13].Importantly, PF has been reported to inhibit high glucose-induced macrophage activation and renal inflammation [14], ameliorate glycemic variability-induced oxidative stress [15], and improve the renal biochemical and pathological damage [16]. Although the existing evidence shows that PF has a therapeutic effect on DN, its potential mechanism of action has not been fully clarified. Herein, this study aimed to conduct a systematic review and meta-analysis of the existing literature on PF treatment in DN animal models to evaluate the efficacy and mechanism of PF in DN animal models.

2. Methods

2.1 Data sources and search strategies

We performed literature retrieval from Chinese Science and Technology Journal Database, Chinese Biomedical Database, Wan Fang, China National Knowledge Infrastructure, PubMed, Cochrane Library, EMBASE, and Web of Science from inception to July 2022 to identify animal experimental studies that met the targeted PF treatment for DN. To obtain a complete literature list, we carefully searched for all eligible studies. The search terms used in PubMed were as follows: "Diabetic Nephropathy", "Diabetic Kidney Diseases", "Kidney Diseases, Diabetic", "Intracapillary Glomerulosclerosis", "Glomerulosclerosis, Nodular", "Paeoniflorin", "Paeoniflorin-6'-O-benzene sulfonate" and "Paeoniflorin sulfonate". The specific search methods are summarized in Appendix 1 in S1 File.

2.2 Eligibility criteria

The selection criteria were as follows: (1) Population (P): establishment of DN rodent models in a generally accepted manner; (2) Intervention (I) and Control (C): the experimental group received treatment with PF single agent or derivative at any dose, and the model group received treatment with an equal amount of nonfunctional substances (normal saline) or did not receive treatment; (3) Results (R): the primary outcome measures of the study were changes in histopathology, morphology, and renal function parameters, including 24-h urinary protein excretion rate, etc., while the reno-protective mechanism of PF against DN was selected as the secondary outcome measures, including the changes in metabolic parameters, biochemical parameters, and inflammatory and oxidative stress markers.

The exclusion criteria were as follows: (1) Population (P): the target disease was not DN (no DN pattern); (2) Intervention (I): PF-based prescription or combination therapy with other drugs; (3) Control (C): unclear comparison with other drugs (e.g., Western pharmaceuticals, combination therapies from traditional Chinese medicine); (4) Outcome (O): no predefined outcome index or no data available; (5) Study design and format: non in vivo studies (in vitro studies, clinical trials, review articles, case reports, meta-analyses, reviews, commentaries, abstracts, editorials, multiple publications, or patents). Notably, although a variety of Paeonia species have been widely used in folk medicine, the extracts of these plants have not been used in clinical trials alone currently, but are often used as part of a prescription. However, the combined application of multiple traditional Chinese medicines in a prescription does not seem to prove the medicinal value of a single herb. Therefore, we excluded clinical trials that included PF compounds. Detailed characteristics of the inclusion and exclusion criteria are shown in Table 1.

	Inclusion criteria	Exclusion criteria
Population (P)	Establishment of DN rodent models in a generally accepted manner	The target disease was not DN (no DN pattern)
Intervention (I)	The experimental group received treatment with PF single agent or	PF-based prescription or combination therapy with other drugs
Control (C)	derivative at any dose. The model group received treatment with an equal amount of nonfunctional substances (normal saline) or did not receive treatment	Unclear comparison with other drugs (Western pharmaceuticals, combination therapies from traditional Chinese medicine)
Outcome (O)	Main outcome measures: changes in histopathology, morphology, and renal function parameters (24-hour urinary protein excretion rate). Secondary outcome measures: metabolic parameters, biochemical parameters, and inflammatory and oxidative stress markers.	No predefined outcome index or no available data
Study design and format	Vivo studies	Non in vivo studies

Table 1. Literature inclusion and exclusion criteria.

https://doi.org/10.1371/journal.pone.0282275.t001

2.3 Data extraction

Two trained and qualified researchers (ZY and JX) performed literature screening and data extraction independently in strict accordance with the inclusion/exclusion criteria. Any disagreement was resolved by the third party (JG). All eligible articles were independently evaluated from the following aspects: (1) The year of publication and the name of the first author; (2) Details of animals (quantity, species, sex, and weight); (3) The method of establishing animal model and the standard of successful modeling; (4) The use of anesthetics in the process of the experiment; (5) Treatment group and control group; (6) Primary and secondary outcomes and intergroup differences. If the results were shown by gradient drug doses or multiple time points, only the final measurement data for the highest dose of drugs were used. If the documentation data were in the form of graphs, we attempted to obtain the data from the original author. If the raw data could not be acquired, the numerical values were measured from the graphs by using the publicly available Webplotdigitizer was used for measurement. The final results were presented graphically, not in digital text. The remaining 62 studies.

2.4 Risk of bias in individual study

Two qualified researchers (BQ and ZY) assessed the risk of bias for each included study using the CAMARADES 10-item quality checklist [17] with minor modifications: A: peer-reviewed publication; B: control of laboratory temperature; C: random allocation to treatment or control; D: blinded modeling (modelling by randomisation or use of transgenic knockout mice); E: blinded assessment of outcomes; F: use of anaesthetics without nephroprotective activity or nephrotoxicity; G: selection of a reasonable animal model (old age, hyperlipidemia, or hypertension); H: sample size calculation; I: compliance with animal experimental welfare regulations (\geq three of the following: nutrition, disinfection, ambient temperature and humidity, preoperative anesthesia, postoperative analgesia, and finally euthanasia); J: declaration of potential conflicts of interest. Each study received a maximum quality score of 10 points, and the median of the calculated results was taken. Any disagreement during data extraction and quality assessment was resolved by consensus or third arbitration between the authors (JG and JZ).

2.5 Statistical analysis

We downloaded and used Revman 5.3 software on the official website to perform statistical analysis on the extracted data. Considering the differences in measurement instrument and animal modeling, we quantitatively determined the summary statistics of the results using the standardized mean difference (SMD) with 95% confidence interval (95% CI). A value of

p < 0.05 indicated that the difference between the experimental and model groups was statistically significant. The heterogeneity between studies was assessed using the I² statistical test. If $I^2 \le 50\%$, it was indicative of no significant heterogeneity, and a fixed effects model was employed to combine effect sizes. If $I^2 > 50\%$, it was suggested that the included studies were of different quality, and a random effects model was adopted, or sensitivity analyses were performed. We performed subgroup analyses for modeling methods, animal species, PF doses, and treatment duration to explore the sources of heterogeneity. In addition, time dose interval analysis was performed using Origin 2021 software.

3.Results

3.1 Research retrieval

We retrieved 132 potentially relevant studies from eight databases. After reviewing titles and abstracts, we excluded 60 duplicate or irrelevant studies. The remaining 62 studies were reviewed in full-text, 48 of which were not considered because they were not TCM monomer studies or did not include animal models. Finally we identified 9 eligible studies, including 5 studies in English [18–26]. The specific retrieval process is shown in Fig 1.

3.2 Characteristics of included studies

A total of 9 studies involving 526 animals were finally included. The sample size of each study varied from 8 to 12 animals. Male C57BL/6 mice were used in 6 studies; Sprague Dawley (SD) rats were used in 2 studies; male TLR4^{-/-} mice were used in 1 study and male TLR2^{-/-} mice were used in 1 study; male db/db mice were used in 1 study. Seven studies used spontaneous diabetic mutant or transgenic mice (1 study used db/db mice and 6 studies used C57BL/6 mice, of which 2 studies used male TLR4^{-/-} mice versus male TLR2^{-/-} mice, respectively). The weight of SD rats was 200–250 g, and the weight of mice was 18–20 g. Eight studies established DN models by intraperitoneal injection of streptozotocin (STZ); 1 study used a high-fat diet for several weeks and intraperitoneal injection of STZ. For the induction of anesthesia, 5 studies did not report anesthetics; 3 studies reported sodium pentobarbital and 1 study used CO₂. PF details in each study are shown in Fig 2 and Table 2. Nine studies implemented gradient doses of PF from 5 to 100 mg • kg⁻¹ • d⁻¹ by oral or intragastric administration.

To assess the effect of PF treatment on DN, (1) renal pathology and 24-hour urinary protein were used as the primary outcomes in 7 studies; (2) secondary outcomes were as follows: 1) BG-related parameters: BG reported in 9 studies, glut reported in 1 study, FIN reported in 1 study, and HOMA-IR reported in 1 study; 2) kidney function measures: BUN reported in 2 studies, SCr reported in 1 study, Cr reported in 1 study, UAlb / UCR reported in 1 study, KW / BW ratio reported in 2 studies, and TGF- β 1 reported in 1 study; 3) anti-inflammatory factor indicators and downstream factors: TNF- α in 6 studies, IL-1 β in 6 studies, MCP-1 in 7 studies, IL-6 in 1 study, GRK2 in 1 study, and SIRT1 in 1 study; 4) indicators of macrophage activation: iNOS in 6 studies, CD68 in 6 studies, and ICAM1 in 1 study; 5) TLR2 versus TLR4 signaling pathways and protein expression: TLR2 in 3 studies, and TRIF in 3 studies; 6) JAK2 / STAT3 signaling-related proteins: p-JAK2 in 2 studies, p-JAK2 / JAK2 in 2 studies, and p-STAT3 / STAT3 in 2 studies; 7) NF- κ B signaling pathway proteins: NF- κ B-p65 in 5 studies and NF- κ B-p65 in 4 studies; 8) oxidative stress indicators: SOD in 1 study, Nrf2 in 1 study, and GSH-PX in 1 study. Detailed characteristics of included studies are shown in Table 3.

3.2.1 Study quality. The CAMARADES 10-item quality checklist was used for the assessment of risk of bias in each study. The fulfilled criterion scores ranged from 4 / 10 to 7 / 10,



Fig 1. Summary of the process for identifying candidate studies.

with an average of 5.44. Judgments about the risk of bias items for each included study are detailed in Table 4.

3.3 Effectiveness and mechanism

3.3.1 Pathology analysis and clinical parameters. *3.3.1.1 Renal pathology.* Among the 9 studies, 5 studies found that PF treatment significantly attenuated the renal histopathological changes compared with the model group, with a significant reduction in mesangial expansion index (Fig 3A) (n = 120, SMD-4.14, 95% CI (-5.88, -2.41), p < 0.00001; heterogeneity: $\chi^2 = 27.99$, $I^2 = 86\%$) and tubulointerstitial injury index scores (Fig 3B) (n = 120, SMD -6.69, 95% CI (-9.53, -3.86), p < 0.00001; heterogeneity: $\chi^2 = 39.99$, $I^2 = 90\%$). Both mesangial expansion and tubulointerstitial damage indices are strongly associated with renal impairment [27]. Of the 5 studies, 2 studies showed that PF treatment reduced glomerular volume and inhibited mesangial and basement membrane proliferation; 1 study showed that PF treatment reduced extracellular matrix; 1 study reported that PF attenuated renal interstitial congestion, tubular epithelial edema, and inflammatory cell infiltration. The above research findings suggested that PF might significantly prevent DN.

https://doi.org/10.1371/journal.pone.0282275.g001



Fig 2. Study characteristics of eligible studies. Model species and strains(A); Duration of intervention(B);Sex/Gender (C);Methods of model establishment(D).

https://doi.org/10.1371/journal.pone.0282275.g002

3.3.1.2 24-h urinary protein. A meta-analysis of 9 studies showed that mice in the PF intervention group had significantly lower levels of 24-h urinary protein than did mice in the model group (Fig 4A) (n = 200, SMD -9.21, 95% CI (-12.41, -6.00), p<0.00001; heterogeneity: $\chi^2 = 21.16$, $I^2 = 93\%$). Subsequently, we performed sensitivity analysis on BG and 24-h urinary indicators. However, there was no significant decrease in heterogeneity after the elimination of any studies.

Study(years)	specifications	Source	Purity (%)	Quality control reported
(Yang2018)	Powder	Beijing Zhongshan Jin qiao Biotechnology Co., Ltd	NM	?
(Huang2020)	Powder	the Chemistry Lab of the institute of Clinical Pharmacology of Anhui Medical University	NM	HPLC
(Zhao2022)	Powder	China Institute for Food and Drug Control.	NM	?
(Duan2018)	Powder	Nanjing Guanrun Biological Products Co., Ltd.	NM	HPLC-DAD, HPLC-ELSD
(Fu2009)	Powder	Xuan Cheng Baicao Plants Industry and Trade, Anhui, China.	95%	HPLC
(Y. Shao 2017)	Powder	Nanjing GOREN BIO Technology Co., Ltd. (Nanjing, China).	98.78%	HPLC
(Zhang2017)	Powder	Nanjing GOREN BIO Technology Co., Ltd (Nanjing, China).	98.78%	HPLC
(Y. Shao 2019)	Powder	Nanjing GOREN BIO Technology Co., Ltd. (Nanjing, China).	98.78%	HPLC
(Li2018)	Powder	Nanjing GOREN BIO Technology Co., Ltd. (Nanjing, China).	98.78%	HPLC

Table 2. Information of PF of each study	Table 2.	Information	of PF of	each study
--	----------	-------------	----------	------------

Note: Abbreviations (see Appendix 1 in S1 File);—Data not reported; NM: Not mentioned; p < 0.05 represents the statistical difference.

https://doi.org/10.1371/journal.pone.0282275.t002

(Year of publication)	Species (Sex, n = experimental/ control group)	Weight	Modeling method	Criteria for successful modeling	Anesthetic	Treatment group (Method to astragal sides)	Control group	Outcome index (time)
(Yang2018)	C57BL/6J mice male (12/12)	18-20g	By intraperitoneal injection of STZ (50 mg/kg)	After 5 days of injection and 7 days after the end of injection, the venous blood glucose concentration was detected, which exceeded 16.7 mmol/ l	Phenobarbital sodium	PF (100 mg / kg, QD) was orally administered 5 days after STZ injection for 12 weeks	Equal volume of CPBS was injected 5 days after STZ injection for 12 weeks	Pathological changes of renal tissue; 2. BG; 3. 24-h urinary protein; 4. KW/BW ratio; 5. CD68, p- JAK2, and p-STAT3; 6. TNF- α , IL1- β , MCP-1, and iNOS mRNA; 7. p-JAK2/ JAK2 and p-STAT3/ STAT3
(Huang2020)	C57BL/6J mice male (8/8)	18-20g	By intraperitoneal injection of STZ (60 mg/kg)	3 days after intraperitoneal injection of STZ 60mg / kg for 5 consecutive days, the fasting blood glucose FBG of mice was measured to be \geq 11.1 mmol/l	NM	Phenylsulfonyl PF (CP-25) (70 mg / kg, QD)was orally administered after STZ injection for 5 weeks	Equal volume of CMC administered after STZ injection for 5 weeks	1. Body weight and BG; 2. IPGTT and AUC; 3. FBG, FIN, and HOMA-IR; 4. renal volume and renal index; 5. UAlb / Ucr; 6. SCR, BUN, Chol, and TG; 7. Nephron and GRK2; 8. INR, p-IRS1, and PI3K
(Li2018)	C57BL / 6J mice male (12/12)	18-20g	By intraperitoneal injection of STZ (50 mg/kg)	After 5 days of injection and 7 days after the end of injection, the venous blood glucose concentration was detected, which exceeded 16.7 mmol/ l	NM	PF (100 mg / kg, QD) was orally administered 5 days after STZ injection for 12 weeks	Equal volume of CPBS was injected 5 days after STZ injection for 12 weeks	Pathological changes of renal tissue; 2. BG; 3. KW/BW ratio; 4. 24-h urinary protein; 5. CD68, p- JAK2, p-STAT3, JAK2, and STAT3; 6. TNF- α , IL1- β , MCP- 1, and iNOS mRNA
(Zhao2022)	SD rats male (10/10)	200 ± 20 m g	By intraperitoneal injection of STZ (60 mg/kg)	After 72 hours of injection the venous blood glucose concentration was detected, which exceeded 16.7 mmol/ l	NM	PF (100 mg / kg, QD) was orally administered after STZ injection for 8 weeks	Captopril (30mg/kg) was administered after STZ injection for 8 weeks	BG; 2. 24-h urinary protein, 3. BUN and Cr; 4. Pathological observation of renal tissue; 5. TNF- α , IL- 1 β and IL-6; 4. SOD and GSH–Px; 5. SIRT1, Nrf2, and NF-kBp65
(Duan2018)	C57BL/6J mice male (12/12)	18-20g	By intraperitoneal injection of SΓΖ (50 mg/kg)	After 5 days of injection and 7 days after the end of injection, the venous blood glucose concentration was detected, which exceeded 16.7 mmol/ l	NM	PF (100 mg / kg, QD) was orally administered 5 days after STZ injection for 12 weeks	By oral gavage of an equal volume of distilled water for 12 weeks	1. Pathological changes of renal tissue; 2. BG; 3. 24-h urinary protein; 4. KW/BW ratio; 5. TNF- α , MCP-1, and IL-1 β mRNA; 6. TLR2, MyD88, P-IRAK-1, NF-kBp- p65, and NF-kBp65

Table 3. Characteristics of the included studies.

(Continued)

(Year of publication)	Species (Sex, n = experimental/ control group)	Weight	Modeling method	Criteria for successful modeling	Anesthetic	Treatment group (Method to astragal sides)	Control group	Outcome index (time)
(Fu2009)	SD rats female (10/10)	220- 250g	By intraperitoneal injection of STZ (65 mg/kg)	After 3days of injection and 7 days after the end of injection, the venous blood glucose concentration was detected, which exceeded 16 mmol/l	CO2	PF (20 mg / kg, QD) was orally administered after injection for 8weeks	By oral gavage of an equal volume of distilled water for 8 weeks	Pathological changes of renal tissue; 2. Body weight; 3. Kidney weight; 4. BP; 5. BG; 6. Urinary albumin: creatinine ratio; 7. TGF- β , type IV collagen, and ICAM1; 8. MCP1; 9. NF κ B and macrophages (ED1-positive cells)
(Y. Shao2017)	wild-type (TLR2-/-)and C57BL/6J mice male (12/12)	18-20g	By intraperitoneal injection of STZ (50 mg/kg)	After 5 days of injection and 7 days after the end of injection, the venous blood glucose concentration was detected, which exceeded 16.7 mmol/ l	Phenobarbital sodium	PF (100 mg / kg, QD) was orally administered 5 days after STZ injection for 12 weeks	Equal volume of CPBS was injected 5 days after STZ injection for 12 weeks	Pathological changes of renal tissue; 2. BG; 3 24-h urinary protein; 4. TLR2, NF- κ Bp65, and CD-68; 5.TNF- α , MCP-1, IL-1 β , and iNOS; 6.TLR2, MyD88, p-IRAK1, Trif, p-IRF3, NF- κ Bp-p65, and NF- κ Bp65
(Zhang2017)	db/db mice male (12/12)	NM	NM	Blood glucose levels were over 16.7 mmol/L	NM	PF (60 mg / kg, QD) was orally administered for 12 weeks	By oral gavage of an equal volume of distilled water for 2 weeks	BG; 2. Body weight; 3. Kidney weight; 4. 24-h urinary protein; 5. Cr; 6. TLR2, TLR4, CD-68, and NF- κ Bp65; 7. iNOS, TNF- α , IL-1 β , and MCP-1; 8. TLR2 and TLR4; 9. MyD88, p-IRAK1, Trif, p-IRF3, NF- κ Bp-p65, and IL-1 β
(Y. Shao2019)	C57BL/6J mice and C57BL/10ScN mice males (12/12)	18-20g	By intraperitoneal injection of STZ (50 mg/kg)	NM	Phenobarbital sodium	PF (100 mg / kg, QD) was orally administered 5 days after STZ injection for 12 weeks	By oral gavage of an equal volume of distilled water for 12 weeks	Pathological changes of renal tissue; 2. BG; 3 24-h urinary protein; 4. TNF- α , IL-1 β , MCP-1, and iNOS mRNA; 5. MyD88, p-IRAK1, Trif, p-IRF3, NF- κ Bp-p65, and NF- κ Bp65

Table 3. (Continued)

Note: Abbreviations (see Appendix 1 in S1 File);-Data not reported; NM: Not mentioned; p < 0.05 indicates statistical difference.

https://doi.org/10.1371/journal.pone.0282275.t003

3.3.1.3 *KW/BW ratio*. A meta-analysis of 5 studies showed that mice in the PF intervention group had significantly lower levels of KW/BW ratio than did mice in the model group (Fig 4B) (n = 120, SMD -0.57, 95% CI (-0.93, -0.20), p = 0.002; heterogeneity: $\chi^2 = 0.02$, $I^2 = 0\%$).

3.3.1.4 BUN. A meta-analysis of 2 studies showed that mice in the PF intervention group had significantly lower levels of BUN than did mice in the model group (Fig 4C) (n = 36, SMD -11.88, 95% CI (-27.69,3.94), p = 0.14; heterogeneity: $\chi^2 = 14.20$, $I^2 = 93\%$).

Table 4. Risk of bias of the included studies.

(Years)	Α	В	С	D	E	F	G	Н	I	J	Total
(Yang2018)	\checkmark	\checkmark	\checkmark			\checkmark			\checkmark		6
(Li2018)	\checkmark	\checkmark	\checkmark	\checkmark					\checkmark		5
(Huang2020)	\checkmark		\checkmark	\checkmark			\checkmark		\checkmark		5
(Zhao2022)	\checkmark	\checkmark	\checkmark								4
(Duan2018)	\checkmark	\checkmark	\checkmark	\checkmark					\checkmark		5
(Fu2009)	\checkmark	\checkmark	\checkmark	\checkmark		\checkmark			\checkmark		6
(Y. Shao2017)	\checkmark	\checkmark	\checkmark			\checkmark			\checkmark	\checkmark	7
(Zhang2017)	\checkmark	\checkmark	\checkmark	\checkmark					\checkmark		5
(Y. Shao2019)	\checkmark	\checkmark	\checkmark	\checkmark		\checkmark			\checkmark		6

Studies fullfiling the criteria of: A peer-reviewed publication; B: control of temperature; C: random allocation to treatment or control; D: blinded induction of model (group randomly after modeling or transgenic mice or knockout mice); E: blinded assessment of outcome; F: use of anesthetic without significant renal protective activity or nephrotoxicity; G: appropriate animal model (aged, hyperlipemia, or hypertensive); H: sample size calculation; I: compliance with animal welfare regulations (including three or more of the following points: preoperative anesthesia, postoperative analgesia, nutrition, disinfection, environment temperature, environment humidity, circadian rhythm, and euthanasia); J: statement of potential conflict of interests.

https://doi.org/10.1371/journal.pone.0282275.t004

3.3.1.5 *BG*. A meta-analysis of 9 studies found no significant differences in BG levels between the PF intervention and model groups (p > 0.05) (Fig 4D) (n = 200, SMD 0.26, 95% CI (-0.06, 0.59), p = 0.11; heterogeneity: $\chi^2 = 10.33$, $I^2 = 23\%$).

3.3.2 Anti-inflammation. *3.3.2.1 mRNA expressions of IL-1 \beta and TNF-\alpha.* Of the 9 studies, 6 studies focused on the changes in IL-1 β mRNA expression in the PF treatment group. After sensitivity analysis, 1 study was removed due to that the modeling methods, animal species, high and low PF doses, and length of treatment duration in this study were different from those in other studies. Subsequently, the heterogeneity of IL-1 β mRNA expression across studies was decreased substantially (Table 5 and Fig 5A) (n = 120, SMD-29.28, 95% CI (-33.36, -25.20), *p* < 0.00001; heterogeneity: $\chi^2 = 1.07$, $I^2 = 0\%$). Of the 9 studies, 7 studies focused on the changes in TNF- α mRNA expression in the PF treatment group. After sensitivity analysis, 2 studies were removed separately because the modeling methods, animal species, high and

A: The glomerular mesangial expansion index

	Expe	Experimental Model		0	Std. Mean Difference	Std. Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Duan 2018	1.14	0.14	12	2.15	0.18	12	18.1%	-6.05 [-8.08, -4.01]	
Li 2018	1.19	0.08	12	2.18	0.66	12	22.3%	-2.03 [-3.05, -1.02]	-
Yang2018	1.17	0.13	12	2.16	0.59	12	22.2%	-2.24 [-3.30, -1.18]	-
Yun 2017	1.17	0.17	12	2.16	0.19	12	19.1%	-5.30 [-7.13, -3.48]	
Yun2019	1.16	0.13	12	2.16	0.19	12	18.3%	-5.93 [-7.93, -3.93]	
Total (95% CI)			60			60	100.0%	-4.14 [-5.88, -2.41]	◆
Heterogeneity: Tau ² =	3.26; 0	Chi ² =	27.99,		-10 -5 0 5 10				
Test for overall effect:	Z = 4.6	57 (P <	0.000		Favours [experimental] Favours [Model]				

B: The tubulointerstitial damage index

	Expe	erimen	ital		Model			Std. Mean Difference	Std. Mean	Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Rando	m, 95% CI	
Duan 2018	1.01	0.13	12	2.44	0.14	12	17.9%	-10.22 [-13.48, -6.96]			
Li 2018	1.03	0.28	12	2.46	0.51	12	22.3%	-3.36 [-4.67, -2.05]			
Yang2018	1.01	0.34	12	2.43	0.55	12	22.5%	-3.00 [-4.22, -1.77]			
Yun 2017	1	0.14	12	2.43	0.15	12	18.4%	-9.52 [-12.57, -6.46]			
Yun2019	1.01	0.13	12	2.41	0.17	12	18.9%	-8.93 [-11.81, -6.05]			
Total (95% CI)			60			60	100.0%	-6.69 [-9.53, -3.86]	•		
Heterogeneity: Tau ² =	8.93; 0	Chi² =	39.99,	%	30 10	10	20				
Test for overall effect	Z = 4.6	53 (P <	0.000	Favours [experimental]	Favours [Model]	20					

Fig 3. The forest plot: Effects of PF on mesangial expansion index and tubulointerstitial injury index compared with the model group.

https://doi.org/10.1371/journal.pone.0282275.g003

A. 24-h urinary protein

	Experimental		N	lodel			Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Duan 2018	0.32	0.1	12	1.69	0.01	12	8.9%	-18.61 [-24.43, -12.80]	←	
Fu 2009	204.52	35.71	10	498.07	58.32	10	11.9%	-5.81 [-8.01, -3.62]		
Huang 2020	48.69	7.25	8	58.55	3.77	8	12.4%	-1.61 [-2.79, -0.44]		
Li 2018	0.32	0.09	12	1.69	0.13	12	10.8%	-11.83 [-15.58, -8.08]		
Tingmin 2017	456.98	55.46	12	1,144.5	81.3	12	11.3%	-9.54 [-12.60, -6.48]		
Yang2018	0.32	0.08	12	1.69	0.13	12	10.7%	-12.26 [-16.13, -8.38]		
Yun 2017	0.31	0.09	12	1.68	0.13	12	10.8%	-11.83 [-15.58, -8.08]		
Yun2019	0.31	0.1	12	1.69	0.13	12	10.9%	-11.49 [-15.13, -7.84]		
Zhao 2022	35.59	9.27	10	76.41	11.32	10	12.3%	-3.78 [-5.35, -2.21]	-	
Total (95% CI)			100			100	100.0%	-9.21 [-12.41, -6.00]	◆	
Heterogeneity: Tau ² =	21.16; 0	$hi^2 = 1$	15.57,	df = 8 (P			_			
Test for overall effect:	Z = 5.63	(P < 0.	00001)						Favours [experimental] Favours [Model]	1

B.KW/BWratio

	Expe	Experimental		Model			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Duan 2018	0.77	0.13	12	0.84	0.11	12	20.0%	-0.56 [-1.38, 0.26]	
Li 2018	0.77	0.13	12	0.84	0.11	12	20.0%	-0.56 [-1.38, 0.26]	
Yang2018	0.77	0.13	12	0.84	0.11	12	20.0%	-0.56 [-1.38, 0.26]	
Yun 2017	0.77	0.11	12	0.84	0.11	12	19.8%	-0.61 [-1.44, 0.21]	
Yun2019	0.77	0.13	12	0.84	0.12	12	20.1%	-0.54 [-1.36, 0.28]	
Total (95% Cl) 60 60 Heterogeneity: Chi ² = 0.02, df = 4 (P = 1.00); l ² = 0% 7 8 Test for overall effect: Z = 3.04 (P = 0.002) 8 8								-0.57 [-0.93, -0.20]	Favours [experimental] Favours [Model]

C.BUN

	Experimental Model							Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random,	95% CI	
Huang 2020	3.27	0.17	8	8.42	0.29	8	46.8%	-20.48 [-28.72, -12.25]			
Zhao 2022	8.05	1.33	10	14.06	1.34	10	53.2%	-4.31 [-6.04, -2.58]	=		
Total (95% CI)			18			18	100.0%	-11.88 [-27.69, 3.94]			
Heterogeneity: Tau ² =	121.5	7; Chi ²	= 14.2	0, df =	1 (P =	0.000	2); $I^2 = 93$	3%	10 10	10	
Test for overall effect:	Z = 1.4		Favours (experimental) Fi	avours IM							



D. Blood glucose

	Experimental		N	lodel		:	Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	
Duan 2018	30	2.4	12	30	5.07	12	12.5%	0.00 [-0.80, 0.80]		
Fu 2009	29.18	20.38	10	12.7	23.9	10	9.7%	0.71 [-0.20, 1.62]		
Huang 2020	25.02	1.92	8	23.97	1.66	8	7.9%	0.55 [-0.45, 1.56]		
Li 2018	30.46	3.28	12	30.84	5.07	12	12.5%	-0.09 [-0.89, 0.71]		
Tingmin 2017	33.46	3.28	12	30.81	5.05	12	11.9%	0.60 [-0.22, 1.42]		
Yang2018	30.46	2.45	12	30.84	5.07	12	12.5%	-0.09 [-0.89, 0.71]		
Yun 2017	30.42	2.46	12	30.81	5.05	12	12.5%	-0.09 [-0.90, 0.71]		
Yun2019	30.49	1.4	12	30.84	5.1	12	12.5%	-0.09 [-0.89, 0.71]		
Zhao 2022	28.17	9.62	10	15.92	6.83	10	8.0%	1.41 [0.40, 2.41]		
Total (95% CI)			100			100	100.0%	0.25 [-0.03, 0.53]	◆	
Heterogeneity: Chi ² =	10.31,	df = 8 (l								
Test for overall effect:	Z = 1.7	4 (P = 0)	Favours (experimental) Favours (Model)							

Fig 4. The forest plot: Effects of PF for decreasing 24-h urinary protein, KW/BW ratio, BUN, and BG compared with the model group.

https://doi.org/10.1371/journal.pone.0282275.g004

low PF doses, and length of treatment duration in these two studies were different from others. Subsequently, the heterogeneity of TNF-a mRNA expression was decreased substantially (Table 5 and Fig 5B) (n = 120, SMD-55.99, 95% CI (-63.77, -48.20), *p* < 0.00001; heterogeneity: $\chi^2 = 1.61, I^2 = 0\%$).

Table 5. List of the anti-inflammatory effect of PF and its inhibition on macrophage activation.

Variables	Experiments(n)	Individuals (n)	SMD	95% CI	P-value	Heterogeneity
(1) Effect on i	inflammatory markers				·	
IL-1β	5	120	-29.28	(-33.36, -25.20)	P < 0.00001	$\chi^2 = 1.07, I^2 = 0\%$
TNF-α	5	120	-55.99	(-63.77, -48.20)	P < 0.00001	$\chi^2 = 1.61, I^2 = 0\%$
MCP-1	5	120	-1.90	(-1.96, -1.85)	P < 0.00001	$\chi^2 = 1.67, I^2 = 0\%$
(2) Effect on a	macrophage infiltration				·	
CD68	6	144	-3.72	(-4.30, -3.14)	P<0.00001	$\chi^2 = 3.45, I^2 = 0\%$
iNOS	4	96	-33.0	(-38.34, -27.75)	P<0.00001	$\chi^2 = 9.84, I^2 = 69\%$

https://doi.org/10.1371/journal.pone.0282275.t005

-50 -25

Favours [experimental] Favours [Model]

A. IL-1β

	Expe	Experimental Model						Std. Mean Difference	Std. Mean	Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed	d, 95% CI
Duan 2018	2.82	0.15	12	6.52	0.07	12	18.5%	-30.52 [-40.00, -21.04]		
Li 2018	2.73	0.19	12	6.53	0.05	12	24.7%	-26.41 [-34.62, -18.20]		
Yang2018	2.74	0.18	12	6.55	0.05	12	22.2%	-27.85 [-36.50, -19.19]		
Yun 2017	0.86	0.24	12	6.53	0.04	12	17.0%	-31.82 [-41.70, -21.94]		
Yun2019	2.76	0.16	12	6.5	0.03	12	17.5%	-31.37 [-41.11, -21.63]		
Total (95% CI)			60			60	100.0%	-29.28 [-33.36, -25.20]	◆	
Heterogeneity: Chi ² =	1.07, d	f = 4 (P = 0.9	$(0); I^2 =$	0%					25 50
Test for overall effect:	Z = 14	.07 (P	< 0.00	001)					-50 -25 Favours (experimental)	Eavours [Model]
									Tavours [experimental]	Tavou's [model]
B.TNF-a										
	Expe	erimen	tal	N	lodel			Std. Mean Difference	Std. Mean	Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed	I, 95% CI
Duan 2018	1.79	0.07	12	5.07	0.04	12	20.5%	-55.55 [-72.76, -38.34]	_	
Li 2018	1.77	0.04	12	5.06	0.07	12	20.4%	-55.72 [-72.98, -38.46]	_	
Yang2018	1.78	0.07	12	5.1	0.03	12	17.8%	-59.52 [-77.96, -41.09]	_ _	
Yun 2017	1.79	0.02	12	5.11	0.09	12	26.1%	-49.17 [-64.41, -33.93]		
Yun2019	1.75	0.05	12	5.09	0.05	12	15.2%	-64.50 [-84.47, -44.52]	← • ──	

60 100.0% -55.99 [-63.77, -48.20]

C.MCP-1

Yun2019 Total (95% Cl)

	Expe	erimen	tal		Model			Mean Difference	Mean D	Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixe	d, 95% CI	
Duan 2018	2.2	0.15	12	4.04	0.13	12	22.4%	-1.84 [-1.95, -1.73]	+		
Li 2018	2.11	0.17	12	4.02	0.11	12	21.5%	-1.91 [-2.02, -1.80]	-		
Yang2018	2.13	0.18	12	4.04	0.12	12	18.8%	-1.91 [-2.03, -1.79]			
Yun 2017	2.13	0.18	12	4.05	0.13	12	17.9%	-1.92 [-2.05, -1.79]			
Yun2019	2.09	0.16	12	4.03	0.14	12	19.5%	-1.94 [-2.06, -1.82]			
Total (95% CI)			60			60	100.0%	-1.90 [-1.96, -1.85]	•		
Heterogeneity: Chi ² =	1.67, d	f = 4 (P=0.8	$30); I^2 =$	• 0%						
Test for overall effect:	Z = 70	.21 (P	< 0.00	001)					Favours [experimental	Favours [Model]	-

Fig 5. The forest plot: Effects of PF for decreasing mRNA expressions of IL-1 β , TNF- α , and MCP-1 compared with the model group.

https://doi.org/10.1371/journal.pone.0282275.g005

60

= 0%

Heterogeneity: $Chi^2 = 1.61$, df = 4 (P = 0.81); I^2

Test for overall effect: Z = 14.09 (P < 0.00001)

3.3.2.2 mRNA expression of MCP-1. Of the 9 studies, 7 studies focused on the changes in mRNA expressions of TNF- α and MCP-1 in the PF treatment group. After sensitivity analysis, 2 studies were removed separately because the modeling methods, animal species, doses of PF, and duration of treatment in these 2 studies were different from those in others. Subsequently, the heterogeneity of MCP-1 was decreased substantially (Table 5 and Fig 5C) (n = 120, SMD-1.90, 95% CI (-1.96, -1.85), p < 0.00001; heterogeneity: $\chi^2 = 1.67$, $I^2 = 0\%$).

3.3.3 Inhibition of macrophage activation. *3.3.3.1 Protein expression of CD68.* Of the 9 studies, 6 studies used CD68-positive macrophages as the observation index. A meta-analysis of 6 studies indicated that PF significantly reduced CD68-positive macrophage infiltration in tubulointerstitial areas (Table 5 and Fig 6A) (n = 144, SMD-3.72, 95% CI (-4.30, -3.14), p < 0.00001; heterogeneity: $\chi^2 = 3.45$, $I^2 = 0\%$).

3.3.3.2 mRNA of iNOS. Of the 9 studies, 5 studies focused on the effect of PF treatment on iNOS mRNA expression. After sensitivity analysis, 1 study was removed separately because the modeling methods, animal species, doses of PF, and duration of treatment in this study were different from those in other studies. Subsequently, the heterogeneity of iNOS was decreased substantially (Table 5 and Fig 6B) (n = 96, SMD-33.05, 95% CI (-38.34, -27.75), p < 0.00001; heterogeneity: $\chi^2 = 9.84$, $I^2 = 69\%$).

3.3.4 Inhibition of signaling pathways and protein expressions. *3.3.4.1 TLR2 and TLR4 signaling pathway.* A meta-analysis across the 3 studies indicated that PF significantly reduced TLR2 levels compared with the model group (Table 6 and Fig 7A) (n = 72, SMD-12.32, 95% CI (-14.57, -10.07), p < 0.00001; heterogeneity: $\chi^2 = 0.02$, $I^2 = 0\%$). A meta-analysis across the 2 studies indicated that PF reduced TLR4 levels compared with the model group (Table 6 and Fig 7B) (n = 48, SMD-10.19, 95% CI (-13.61, -6.78), p < 0.00001; heterogeneity: $\chi^2 = 2.09$, $I^2 = 52\%$).

	Expe	erimen	tal		Model			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Duan 2018	2.99	0.48	12	7	1.47	12	18.1%	-3.54 [-4.90, -2.18]	
Li 2018	2.92	0.46	12	6.94	1.42	12	17.2%	-3.68 [-5.07, -2.29]	
Tingmin 2017	5	1.98	12	15.6	1.83	12	9.8%	-5.37 [-7.21, -3.52]	
Yang2018	2.9	0.55	12	6.9	1.48	12	18.6%	-3.46 [-4.80, -2.12]	
Yun 2017	2.9	0.54	12	6.96	1.48	12	18.2%	-3.52 [-4.87, -2.17]	
Yun2019	2.88	0.56	12	6.92	1.46	12	18.1%	-3.53 [-4.88, -2.17]	
Total (95% CI)			72			72	100.0%	-3.72 [-4.30, -3.14]	•
Total (95% CI) Heterogeneity: Tau ² =	= 0.00; 0	Chi² =	72 3.45, c	if = 5 (P = 0.0	72 63); I ² =	100.0% = 0%	-3.72 [-4.30, -3.14]	→ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect	= 0.00; 0 : Z = 12	Chi² = .65 (P	72 3.45, c < 0.00	df = 5 (0001)	P = 0.0	72 63); I ² =	100.0% = 0%	-3.72 [-4.30, -3.14]	-10 -5 0 5 Favours [experimental] Favours [Model]
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect B. iNOS	= 0.00; (: Z = 12	Chi ² = .65 (P	72 3.45, c < 0.00	if = 5 (0001)	P = 0.6	72 63); I ² :	100.0%	-3.72 [-4.30, -3.14]	-10 -5 0 5 Favours [experimental] Favours [Model]
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect B. INOS	= 0.00; (: Z = 12 Expe	Chi ² = .65 (P rimen	72 3.45, c < 0.00 tal	if = 5 (0 0001) Mean	P = 0.0	72 63); I ² : Total	100.0% = 0%	-3.72 [-4.30, -3.14] 	-10 -5 0 5 Favours [experimental] Favours [Model] Std. Mean Difference
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect B. iNOS Study or Subgroup	= 0.00; 0 : Z = 12 Expe Mean	Chi ² = .65 (P rimen <u>SD</u>	72 3.45, c < 0.00 tal Total	if = 5 (0 0001) Mean 4 3	P = 0.6	72 63); I ² : <u>Total</u>	100.0% = 0% <u>Weight</u> 38.6%	-3.72 [-4.30, -3.14] Std. Mean Difference IV, Fixed, 95% CI	-10 -5 0 5 Favours [experimental] Favours [Model] Std. Mean Difference IV, Fixed, 95% Cl
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect 3. iNOS Study or Subgroup Li 2018 Yano2018	= 0.00; 0 : Z = 12 Expe Mean 1.96 2.01	Chi ² = .65 (P rimen SD 0.1	72 3.45, c < 0.00 tal <u>Total</u> 12	if = 5 (1 0001) Mean 4.3 4.3	P = 0.4	72 63); l ² : Total 12 12	100.0% = 0% <u>Weight</u> 38.6% 28.6%	-3.72 [-4.30, -3.14] Std. Mean Difference IV, Fixed, 95% CI -27.40 (-35.91, -18.88) -31.86 [-41.75, -21.97]	-10 -5 0 5 Favours [experimental] Favours [Model] Std. Mean Difference IV, Fixed, 95% Cl
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect 3. iNOS Study or Subgroup Li 2018 Yang2018 Yang2018	= 0.00; 0 : Z = 12 Expe Mean 1.96 2.01 2	Chi ² = .65 (P 	72 3.45, c < 0.00 tal Total 12 12 12	Mean 4.3 4.32	P = 0.4	72 63); l ² : Total 12 12 12	100.0% = 0% <u>Weight</u> 38.6% 28.6% 8.2%	-3.72 [-4.30, -3.14] Std. Mean Difference IV, Fixed, 95% CI -27.40 [-35.91, -18.88] -31.86 [-41.75, -21.97] -59.84 [-78.7 - 41.31]	-10 -5 0 5 Favours [experimental] Favours [Model]
Total (95% CI) Heterogeneity: Tau ² - Test for overall effect 3. iNOS Study or Subgroup Li 2018 Yang2018 Yun 2017 Yun2019	= 0.00; (: Z = 12 Expe Mean 1.96 2.01 2 2.17	Chi ² = .65 (P sriment SD 0.1 0.07 0.05 0.06	72 3.45, c < 0.00 tal Total 12 12 12 12 12	df = 5 (0 0001) Mean 4.3 4.32 4.36 4.69	P = 0.4	72 63); I ² = Total 12 12 12 12	100.0% = 0% Weight 38.6% 28.6% 8.2% 24.6%	-3.72 [-4.30, -3.14] Std. Mean Difference IV, Fixed, 95% CI -27.40 [-35.91, -18.88] -31.86 [-41.75, -21.97] -59.84 [-78.37, -41.31] -34.41 [-45.09, -23.73]	-10 -5 0 5 Favours [experimental] Favours [Model] Std. Mean Difference IV, Fixed, 95% Cl
Total (95% CI) Heterogeneity: Tau ² - Test for overall effect 3. iNOS Study or Subgroup Li 2018 Yang2018 Yun 2017 Yun 2017 Tura2019	= 0.00; (: Z = 12 Expe Mean 1.96 2.01 2 2.17	chi ² = .65 (P .65 (P 0.1 0.07 0.05 0.06	72 3.45, c < 0.00 tal Total 12 12 12 12 12	Mean 4.3 4.32 4.36 4.69	P = 0.4 Iodel SD 0.06 0.07 0.02 0.08	72 63); l ² - Total 12 12 12 12	Weight 38.6% 28.6% 24.6%	-3.72 [-4.30, -3.14] Std. Mean Difference IV, Fixed, 95% CI -27.40 [-35.91, -18.88] -31.86 [-41.75, -21.97] -59.84 [-78.37, -41.31] -34.41 [-45.09, -23.73] -34.61 [-45.09, -23.73]	-10 -5 0 5 Favours [experimental] Favours [Model]

Fig 6. The forest plot: Effects of PF for decreasing mRNA expression of iNOS compared with the model group.

https://doi.org/10.1371/journal.pone.0282275.g006

3.3.4.2 Protein expressions of downstream signal factors-MyD88, p-IRAK1, Trif, and p-IRF3. A meta-analysis across 4 studies indicated that PF reduced MyD88 and p-IRAK1 protein expressions compared to controls. The heterogeneity of MyD88 (Table 6 and Fig 8A) (n = 96, SMD-15.02, 95% CI (-21.07, -8.96), p < 0.00001; heterogeneity: $\chi^2 = 22.28$, $I^2 = 87\%$) did not decrease significantly after elimination of any studies. After sensitivity analysis, 1 study was removed separately due to that the modeling methods, animal species, high and low PF doses, and length of treatment duration in this study were different from those in others. Subsequently, the heterogeneity of p-IRAK1 was decreased substantially (Table 6 and Fig 8B) (n = 72, SMD-4.82, 95% CI (-5.80, -3.83), p < 0.00001; heterogeneity: $\chi^2 = 1.92$, $I^2 = 0\%$). A meta-analysis across 2 studies showed that the PF group had significantly reduced TRIF (Table 6 and Fig 8C) (n = 72, SMD-8.57, 95% CI (-10.83, -6.31), p < 0.00001; heterogeneity: $\chi^2 = 3.87$, $I^2 = 48\%$) and p-IRF3 protein expressions (Table 6 and Fig 8D) (n = 72, SMD-8.60,

Variables	Experiments (n)	Individuals(n)	SMD	95% CI	P-value	Heterogeneity
(1) Effect onTLE	R2 and TLR4 signalin	g pathway	· · ·			
TLR2	3	72	-12.32	(-14.57, -10.07)	P < 0.00001	$\chi^2 = 0.02, I^2 = 0\%$
TLR4	2	48	10.19	(-13.61, -6.78)	P < 0.00001	$\chi^2 = 2.09, I^2 = 52\%$
(2) Effect on dov	wnstream signal facto	ors			·	
MyD88	4	96	-15.02	(-21.07, -8.96)	P < 0.00001	$\chi^2 = 22.28, I^2 = 87\%$
p-IRAK1	3	72	-4.82	(-5.80, -3.83)	P < 0.00001	$\chi^2 = 1.92, I^2 = 0\%$
Trif	3	72	-8.57	(-10.83, -6.31)	P < 0.00001	$\chi^2 = 3.87, I^2 = 48\%$
p-IRF3	3	72	-8.60	(-16.07, -1.13)	P < 0.00001	$\chi^2 = 41.40, I^2 = 95\%$
(3) Effect on JAI	K2/ STAT3 signaling	pathway			·	
p-JAK2 in G	2	48	-6.17	(-6.17, -4.71)	P < 0.00001	$\chi^2 = 0.28, I^2 = 0\%$
p-JAK2 in T	2	48	-4.35	(-5.46, -3.24)	P < 0.00001	$\chi^2 = 0.06, I^2 = 0\%$
p-STAT3 in G	2	48	-0.20	(-0.76, 0.37)	<i>P</i> = 0.95	$\chi^2 = 0, I^2 = 0\%$
p-STAT3 in T	2	48	-8.26	(-10.15, -6.36)	P < 0.00001	$\chi^2 = 0.16, I^2 = 0\%$
(4) Effect on NF	-кВ signaling pathwa	ny				
NF-кВ p65	4	92	-7.87	(-9.21, -6.53)	P < 0.00001	$\chi^2 = 5.46, I^2 = 45\%$
NF-кВ p-p65	3	72	-33.16	(-39.11, -27.20)	P < 0.00001	$\chi^2 = 0.43, I^2 = 0\%$

Table 6. List of the inhibitory effects of PF on signaling pathways and protein expressions.

https://doi.org/10.1371/journal.pone.0282275.t006

A: TLR2

	Expe	rimen	tal	N	/odel			Std. Mean Difference	Std. Mean	Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed	I, 95% CI
Duan 2018	0.51	0.01	12	0.71	0.02	12	33.9%	-12.21 [-16.08, -8.35]		
Tingmin 2017	0.45	0.02	12	0.71	0.02	12	32.2%	-12.55 [-16.52, -8.59]		
Yun 2017	0.5	0.01	12	0.7	0.02	12	33.9%	-12.21 [-16.08, -8.35]		
Total (95% CI)			36			36	100.0%	-12.32 [-14.57, -10.07]	•	
Heterogeneity: Chi ² =	0.02, d	f = 2 (P = 0.9	(99); $I^2 =$	0%				-20 -10 (
Test for overall effect:	Z = 10	.74 (P	< 0.00	001)					Favours [experimental]	Favours [Model]
B: TLR4										
	Expe	erimen	tal		Model			Std. Mean Difference	Std. Mean	Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed	l, 95% CI
Tingmin 2017	0.49	0.02	12	0.67	0.02	12	65.5%	-8.69 [-11.50, -5.88]		
Yun2019	0.48	0.01	12	0.68	0.02	12	34.5%	-12.21 [-16.08, -8.35]		
Total (95% CI)			24			24	100.0%	-9.91 [-12.18, -7.64]	•	

Total (95% CI) 24 Heterogeneity: Chi² = 2.09, df = 1 (P = 0.15); I² = 52% Test for overall effect: Z = 8.55 (P < 0.00001)

Fig 7. The forest plot: Effects of PF for decreasing TLR2 and TLR4 compared with the model group.

https://doi.org/10.1371/journal.pone.0282275.g007

95% CI (-16.07, -1.13), p = 0.02; heterogeneity: $\chi^2 = 41.40$, $I^2 = 95\%$) compared with the model group (p < 0.001).

-20

-10

10

ò

Favours [experimental] Favours [Model]

20

3.3.4.3 JAK2/ STAT3 signaling pathway. A meta-analysis across the 2 studies indicated that PF significantly reduced glomerular (Table 6 and Fig 9A) (n = 48, SMD-6.17, 95% CI (-6.17,

A. MyD88

	Expe	rimen	tal	N	lodel			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Duan 2018	0.43	0.01	12	0.66	0.01	12	21.7%	-22.21 [-29.12, -15.29]	
Tingmin 2017	0.47	0.04	12	0.78	0.03	12	28.5%	-8.47 [-11.20, -5.73]	+
Yun 2017	0.42	0.02	12	0.65	0.02	12	27.5%	-11.10 [-14.63, -7.58]	-
Yun2019	0.4	0.01	12	0.62	0.01	12	22.2%	-21.24 [-27.86, -14.62]	
Total (95% CI)			48			48	100.0%	-15.02 [-21.07, -8.96]	◆
Heterogeneity: Tau ² =	31.46;	Chi ² =	22.28,	df = 3	(P < 0).0001)	$ I^2 = 879$	%	
Test for overall effect:	Z = 4.8	6 (P <	0.0000)1)					Favours [experimental] Favours [Model]
B. p-IRAK1	Exp	erimer	ntal		Model			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Duan 2018									
Dualizoro	0.41	0.04	12	0.55	0.01	12	36.0%	6 -4.64 [-6.28, -2.99]	-
Yun 2017	0.41	0.04	12 12	0.55	0.01	12 12	36.0% 40.6%	6 -4.64 [-6.28, -2.99] 6 -4.27 [-5.82, -2.73]	
Yun 2017 Yun 2019	0.41 0.4 0.41	0.04 0.04 0.03	12 12 12	0.55 0.54 0.55	0.01 0.02 0.01	12 12 12	36.0% 40.6% 23.4%	6 -4.64 [-6.28, -2.99] 6 -4.27 [-5.82, -2.73] 6 -6.05 [-8.08, -4.01]	*
Yun 2017 Yun2019 Total (95% CI)	0.41 0.4 0.41	0.04 0.04 0.03	12 12 12 36	0.55 0.54 0.55	0.01 0.02 0.01	12 12 12 36	36.0% 40.6% 23.4%	 -4.64 [-6.28, -2.99] -4.27 [-5.82, -2.73] -6.05 [-8.08, -4.01] -4.82 [-5.80, -3.83] 	* *
Yun 2017 Yun 2017 Yun 2019 Total (95% Cl) Heterogeneity: Chi ² =	0.41 0.4 0.41	0.04 0.04 0.03	12 12 12 36 (P = 0.3	0.55 0.54 0.55 38); I ² =	0.01 0.02 0.01 = 0%	12 12 12 36	36.0% 40.6% 23.4% 100.0%	 -4.64 [-6.28, -2.99] -4.27 [-5.82, -2.73] -6.05 [-8.08, -4.01] -4.82 [-5.80, -3.83] 	
Yun 2017 Yun2019 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect	0.41 0.4 0.41 1.92, c z = 9.	0.04 0.04 0.03 if = 2 59 (P -	12 12 12 36 (P = 0.3 < 0.000	0.55 0.54 0.55 38); I ² =	0.01 0.02 0.01 = 0%	12 12 12 36	36.0% 40.6% 23.4% 100.0%	 -4.64 [-6.28, -2.99] -4.27 [-5.82, -2.73] -6.05 [-8.08, -4.01] -4.82 [-5.80, -3.83] 	-10 -5 0 5 10 Favours [experimental] Favours [Model]
Yun 2017 Yun2019 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect C.Trif	0.41 0.4 0.41 1.92, c : Z = 9.	0.04 0.04 0.03 if = 2 59 (P -	12 12 12 36 (P = 0.3 < 0.000	0.55 0.54 0.55 38); I ² =	0.01 0.02 0.01	12 12 12 36	36.0% 40.6% 23.4%	6 -4.64 [-6.28, -2.99] 6 -4.27 [-5.82, -2.73] 6 -6.05 [-8.08, -4.01] 6 -4.82 [-5.80, -3.83]	-10 -5 0 5 10 Favours [experimental] Favours [Model]

	Expe	erimen	tal		lodel			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Tingmin 2017	0.45	0.01	12	0.74	0.04	12	30.2%	-9.60 [-12.68, -6.53]		
Yun 2017	0.4	0.04	12	0.62	0.02	12	41.2%	-6.72 [-8.94, -4.49]		
Yun2019	0.49	0.02	12	0.7	0.02	12	28.5%	-10.14 [-13.38, -6.90]		
Total (95% CI)			36			36	100.0%	-8.57 [-10.83, -6.31]	•	
Heterogeneity: Tau ² = Test for overall effect:	= 1.93; 0 Z = 7.4	Chi ² = 43 (P <	3.87, d 0.000	lf = 2 (F 01)	P = 0.1	L4); I ² =	48%		-20 -10 0 10 20 Favours [experimental] Favours [Model]	-

D.p-IRF3

	Expe	erimen	tal		lodel			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Tingmin 2017	0.4	0.03	12	0.67	0.01	12	32.6%	-11.66 [-15.35, -7.96]	_ _
Yun 2017	0.35	0.02	12	0.55	0.01	12	32.3%	-12.21 [-16.08, -8.35]	
Yun2019	0.39	0.1	12	0.57	0.01	12	35.1%	-2.45 [-3.55, -1.34]	+
Total (95% CI)			36			36	100.0%	-8.60 [-16.07, -1.13]	
Heterogeneity: Tau ² =	= 41.04;	Chi ² =	41.40	, df = 2	2 (P <	0.0000	1); $I^2 = 9$	5% -	
Test for overall effect:	Z = 2.2	26 (P =	0.02)						Favours [experimental] Favours [Model]

Fig 8. The forest plot: Effects of PF for decreasing MyD88, p-IRAK1, Trif, and p-IRF3 compared with the model group.

https://doi.org/10.1371/journal.pone.0282275.g008

A. Quantitative analysis of P-JAK2 in glomeruli

	Expe	erimen	tal	M	Model			Std. Mean Difference	Std. Mean	Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed	l, 95% CI
Li 2018	3.43	1.06	12	13.55	1.8	12	44.6%	-6.62 [-8.81, -4.42]		
Yang2018	3.4	1.24	12	13.5	2.02	12	55.4%	-5.82 [-7.79, -3.85]		
Total (95% CI)			24			24	100.0%	-6.17 [-7.64, -4.71]	•	
Heterogeneity: Chi ² = Test for overall effect	0.28, d : Z = 8.2	f = 1 (25 (P <	P = 0.6	50); I ² = 01)	0%				-10 -5 (Favours [experimental]) 5 10 Favours (Model)

B. Quantitative analysis of P-JAK2 in Tubulointerstitial

	Experimental Model							Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Li 2018	6.35	0.99	12	30.75	7.34	12	47.6%	-4.50 [-6.10, -2.89]	
Yang2018	6.4	1.35	12	30.9	7.81	12	52.4%	-4.22 [-5.75, -2.69]	
Total (95% CI)			24			24	100.0%	-4.35 [-5.46, -3.24]	•
Heterogeneity: Tau ² =	0.00; 0	Chi ² =	0.06, d	f = 1 (P)	= 0.8	1); $I^2 =$	0%		
Test for overall effect:	Z = 7.7	70 (P <	0.000	01)					Favours [experimental] Favours [Model]

C. Quantitative analysis of P-STAT3 in Tubulointerstitial

	Expe	rimen	tal	N	Iodel			Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	
Li 2018	4.03	1.18	12	16.22	1.51	12	45.7%	-8.69 [-11.49, -5.88]		
Yang2018	3.9	1.55	12	16.3	1.48	12	54.3%	-7.90 [-10.47, -5.33]		
Total (95% CI)			24			24	100.0%	-8.26 [-10.15, -6.36]	•	
Heterogeneity: Chi ² = Test for overall effect:	0.16, d Z = 8.5	f = 1 (4 (P <	P = 0.6	59); I ² = 01)	0%				-20 -10 0 10 20 Favours [experimental] Favours [Model]	

D.Quantitative analysis of P-STAT3 in glomeruli



Fig 9. The forest plot: Effects of PF for decreasing p-JAK2 and p-STAT3 compared with the model group.

https://doi.org/10.1371/journal.pone.0282275.g009

-4.71), p < 0.00001; heterogeneity: $\chi 2 = 0.28$, $I^2 = 0\%$) and tubulointerstitial (Table 6 and Fig 9B) (n = 48, SMD-4.35, 95% CI (-5.46, -3.24), p < 0.00001; heterogeneity: $\chi 2 = 0.06$, $I^2 = 0\%$) P-JAK2 protein levels compared with controls. Also compared with the model group, PF obviously reduced the levels of tubulointerstitial p-STAT3 protein (Table 6 and Fig 9C) (n = 48, SMD-8.26, 95% CI (-10.15, -6.36), p < 0.00001; heterogeneity: $\chi 2 = 0.16$, $I^2 = 0\%$) but had no obvious effect on glomerular p-STAT3 protein (Table 6 and Fig 9D) (n = 48, SMD-0.20, 95% CI (-0.76, 0.37), p = 0.95; heterogeneity: $\chi 2 = 0$, $I^2 = 0\%$).

3.3.4.4 Protein expression of NF-κB p-p65 and NF-κB p65. A meta-analysis across 5 studies indicated that PF reduced NF-κB-p65 protein compared to controls. After sensitivity analysis, 1 study was removed separately because the modeling methods, doses of PF, animal species, and duration of treatment in this study were varied from those in other studies. Subsequently, the heterogeneity of NF-κB-p65 was decreased substantially (Table 6 and Fig 10A) (n = 92, SMD-7.87, 95% CI (-9.21, -6.53), p < 0.00001; heterogeneity: $\chi^2 = 5.46$, $I^2 = 45\%$). A metaanalysis across 4 studies revealed that PF reduced NF-κB-p-p65 protein compared to controls. After sensitivity analysis, 1 study was removed separately due to that the animal species, modeling methods, doses of PF, and duration of treatment in this study were different from those in others. Subsequently, the heterogeneity of NF-κB-p-p65 was decreased substantially (Table 6 and Fig 10B) (n = 72, SMD-33.16, 95% CI (-39.11, -27.20), p < 0.00001; heterogeneity: $\chi^2 = 0.43$, $I^2 = 0\%$).

3.3.5 Time-dose interval analysis. Notably, the time-dose interval analysis can intuitively display the optimal drug dose and treatment duration for providing optimal efficacy. To

A:	NF-кB-р65	

	Expe	erimen	tal		Model			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Duan 2018	0.55	0.03	12	0.8	0.01	12	15.2%	-10.79 [-14.23, -7.36]	
Yun 2017	0.56	0.03	12	0.8	0.02	12	20.9%	-9.09 [-12.01, -6.16]	
Yun2019	0.28	0.05	12	0.74	0.07	12	31.2%	-7.30 [-9.70, -4.90]	
Zhao 2022	0.21	0.03	10	0.48	0.05	10	32.7%	-6.27 [-8.61, -3.93]	-
Total (95% CI)			46			46	100.0%	-7.87 [-9.21, -6.53]	•
Heterogeneity: Chi ² =	5.46, d	f = 3 (P = 0.3	14); $I^2 =$	45%			-	
Test for overall effect:	Z = 11	53 (P	< 0.00	001)					-20 -10 0 10 20
			< 0.00	001)					ravours (experimental) ravours (model)
3: NF-кB p-р	65		< 0.00						ravours (experimental) ravours (model)
3: NF-кВ р-р	65 Expe	rimen	tal		lodel			Std. Mean Difference	Std. Mean Difference
3: NF-κB p-p	65 Expe Mean	rimen SD	tal Total	Mean	Aodel SD	Total	Weight	Std. Mean Difference IV, Fixed, 95% Cl	Std. Mean Difference IV, Fixed, 95% CI
3: NF-κB p-p Study or Subgroup Duan 2018	65 Expe <u>Mean</u> 0.55	rimen SD	tal Total 12	Mean 0.91	Nodel SD	Total	Weight 30.5%	Std. Mean Difference IV, Fixed, 95% CI -34.76 [-45.54, -23.97]	Std. Mean Difference
3: NF-KB p-p Study or Subgroup Duan 2018 Yun 2017	Expe Mean 0.55 0.55	rimen SD 0.01 0.01	tal Total 12 12	Mean 0.91 0.91	fodel SD 0.01 0.01	Total 12 12	Weight 30.5% 30.5%	Std. Mean Difference IV, Fixed, 95% CI -34.76 [-45.54, -23.97] -34.76 [-45.54, -23.97]	Std. Mean Difference IV, Fixed, 95% Cl
3: NF-кВ p-p <u>Study or Subgroup</u> Duan 2018 Yun 2017 Yun2019	Expe Mean 0.55 0.55 0.76	rimen SD 0.01 0.03	tal Total 12 12 12	Mean 0.91 0.91 1.47	Aodel SD 0.01 0.01 0.01	Total 12 12 12	Weight 30.5% 30.5% 39.1%	Std. Mean Difference IV, Fixed, 95% CI -34.76 [-45.54, -23.97] -34.76 [-45.54, -23.97] -30.66 [-40.18, -21.14]	Std. Mean Difference IV, Fixed, 95% CI
3: NF-кВ р-р <u>Study or Subgroup</u> Duan 2018 Yun 2017 Yun2019 Total (95% Cl)	Expe Mean 0.55 0.55 0.76	erimen SD 0.01 0.01 0.03	tal Total 12 12 12 36	Mean 0.91 0.91 1.47	Aodel SD 0.01 0.01 0.01	Total 12 12 12 36	Weight 30.5% 30.5% 39.1% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -34.76 [-45.54, -23.97] -30.66 [-40.18, -21.14] -33.16 [-39.11, -27.20]	Std. Mean Difference IV, Fixed, 95% Cl
3: NF-кВ р-р <u>Study or Subgroup</u> Duan 2018 Yun 2017 Yun2019 Total (95% CI) Heterogeneity: Chi ² =	65 Expe Mean 0.55 0.55 0.76	$\frac{SD}{0.01}$ 0.01 0.03 f = 2 (1)	tal <u>Total</u> 12 12 12 12 36 P = 0.8	Mean 0.91 0.91 1.47 30); I ² =	Model SD 0.01 0.01 0.01 0.01	Total 12 12 12 36	Weight 30.5% 30.5% 39.1% 100.0%	Std. Mean Difference IV, Fixed, 95% Cl -34.76 [-45.54, -23.97] -34.76 [-45.54, -23.97] -30.66 [-40.18, -21.14] -33.16 [-39.11, -27.20]	Std. Mean Difference IV, Fixed, 95% Cl
3: NF-κB p-p <u>Study or Subgroup</u> Duan 2018 Yun 2017 Yun2019 Total (95% CI) Heterogeneity: Ch ² = Test for overall effect	65 Expe Mean 0.55 0.55 0.76 0.43, d Z = 10.	rimen <u>SD</u> 0.01 0.03 f = 2 (0) .92 (P)	tal <u>Total</u> 12 12 12 12 36 P = 0.8 < 0.00	Mean 0.91 0.91 1.47 30); I ² = 001)	Nodel SD 0.01 0.01 0.01 0.01	Total 12 12 12 36	Weight 30.5% 30.5% 39.1% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -34.76 [-45.54, -23.97] -34.76 [-45.54, -23.97] -30.66 [-40.18, -21.14] -33.16 [-39.11, -27.20]	Std. Mean Difference IV, Fixed, 95% CI

Fig 10. The forest plot: Effects of PF for decreasing NF-κB-p65 and NF-κB p-p65 compared with the model group.

https://doi.org/10.1371/journal.pone.0282275.g010

determine the optimal duration and most reasonable dosage of PF in the treatment of DN, four indicators including mesangial expansion index, tubulointerstitial damage index, 24-h urinary protein, and MCP-1 mRNA were selected for the "time-dose analysis" (Fig 11 and S1-S4 Tables in S1 File). Details on the relationship between the main biochemical markers of renal injury and the dose/time of PF administration is shown in S1-S4 Tables in S1 File. In the analysis of glomerular mesangial dilatation index and renal tubulointerstitial injury index,



Fig 11. The scatter plot of time-dose interval analysis.

https://doi.org/10.1371/journal.pone.0282275.g011

Variables	Experiments(n)	Individuals(n)	SMD	95%CI	P-value	Heterogeneity
species						
C57BL/6J mice	6	136	-4.89	(-5.87, -3.91)	p < 0.00001	$\chi^2 = 104.22, I^2 = 95\%$
SD rats	2	40	-4.47	(-5.75, -3.19)	p < 0.00001	$\chi^2 = 2.18, I^2 = 54\%$
modeling						
STZ = 50 mg/kg	5	120	-12.48	(-14.26, -10.69)	p < 0.00001	$\chi^2 = 4.80, I^2 = 17\%$
STZ > 50 mg/kg	3	56	-2.92	(-3.78, -2.05)	p < 0.00001	$\chi^2 = 12.60, I^2 = 84\%$
Dosage						
PF = 100 mg/kg	6	140	-11.34	(-15.92, -6.76)	p < 0.00001	$\chi^2 = 56.14, I^2 = 91\%$
PF < 100 mg/kg	3	60	-5.48	(-9.99, -0.98)	p = 0.002	$\chi^2 = 28.98, I^2 = 93\%$
Period						
12 weeks	5	120	-12.48	(-14.26, -10.69)	p < 0.00001	$\chi^2 = 4.80, I^2 = 17\%$
<12 weeks	4	80	-3.41	(-4.24, -2.58)	p < 0.00001	$\chi^2 = 29.27, I^2 = 90\%$

Table 7. Stratified analysis of pooled estimates according to24-h urinary protein.

https://doi.org/10.1371/journal.pone.0282275.t007

when the PF dose was maintained at 25~100 mg and the treatment duration was maintained at 12 weeks, the effect of PF treatment group on relieving mesangial expansion and tubuloin-terstitial injury was better than that of the model group (p < 0.05). In the 24-h urinary protein analysis, when the PF dose was maintained at 5~100 mg and the treatment duration was maintained at 2~12 weeks, PF treatment resulted in obvious improving effects on the 24-h urinary protein compared with the model group (p < 0.05). In the MCP-1 mRNA expression analysis, when the PF dose was maintained at 5~100 mg and the treatment duration was maintained at 2~12 weeks, PF treatment exerted significant effects on MCP-1 compared to the model group (p < 0.05).

3.3.6 Subgroup analysis. We explored potential confounders (including modeling method, animal species, PF dose, and treatment duration) that may increase 24-hour urinary protein heterogeneity and then performed subgroup analyses of these factors to explore sources of heterogeneity (Table 7). In the subgroup analysis of different animal species, the groups of C57BL/6J mice (Table 7 and Fig 12A)(n = 136, SMD-4.89, 95% CI (-5.87, -3.91, p < 0.00001; heterogeneity: $\chi 2 = 104.22$, $I^2 = 95\%$) were more heterogeneous than the groups of SD rats (Table 7 and Fig 12A) (n = 40, SMD-4.47, 95% CI (-5.75, -3.19, p < 0.00001; heterogeneity: $\chi 2 = 2.18$, $I^2 = 54\%$). To reduce sensitivity, we excluded the literature that did not meet the regulations before subgroup analysis of various modeling methods [26] because it used the db/db diabetic mouse model and did not mention the relevant choice of modeling reagents. The group of DN mice induced by 50 mg/kg STZ (Table 7 and Fig 12B) (n = 120, SMD-12.48, 95% CI (-14.26, -10.69, p < 0.00001; heterogeneity: $\chi 2 = 4.80$, $I^2 = 17\%$) was less heterogeneous than the group of DN mice induced by > 50 mg/kg STZ (Table 7 and Fig 12B) (n = 56, SMD-2.92, 95% CI (-3.78, -2.05, p < 0.00001; heterogeneity: $\chi 2 = 12.60$, $I^2 = 84\%$). Before subgroup analysis of PF doses, we deleted the literature (Huang et al., 2020) because it used a derivative of paeoniflorin (CP-25) to reduce sensitivity. We found that the heterogeneity was not obviously different between the 100 mg/kg PF group (Table 7 and Fig 13A) (n = 140, SMD-11.34, 95% CI (-15.92, -6.76, p < 0.00001; heterogeneity: $\chi^2 = 56.14$, $I^2 = 91\%$) and the < 100 mg/kg PF group (Table 7 and Fig 13A) (n = 60, SMD-5.48, 95% CI (-9.99, -0.98, p = 0.002; heterogeneity: $\chi 2 = 28.98$, $I^2 = 93\%$). In the subgroup analysis of duration of treatment, we could see that the group with 12 weeks of treatment (Table 7 and Fig 13B) (n = 120, SMD-12.48, 95% CI (-14.26, -10.69, p < 0.00001; heterogeneity: $\chi^2 = 4.80$, $I^2 = 17\%$) had a significantly lower heterogeneity than the the group with < 12 weeks of treatment (Table 7 and Fig 13B) (n = 80, SMD-3.41, 95% CI (-4.24, -2.58, p < 0.00001; heterogeneity: $\chi^2 = 29.27$, $I^2 =$

A. different animal species

	Expe	rimenta	al	м	odel			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.1.1 C57BL/6J mice									
Duan 2018	0.32	0.1	12	1.69	0.01	12	15.3%	-18.61 [-24.43, -12.80]	(
Huang 2020	48.69	7.25	8	58.55	3.77	8	17.8%	-1.61 [-2.79, -0.44]	+
Li 2018	0.32	0.09	12	1.69	0.13	12	16.7%	-11.83 [-15.58, -8.08]	
Yang2018	0.32	0.08	12	1.69	0.13	12	16.7%	-12.26 [-16.13, -8.38]	
Yun 2017	0.31	0.09	12	1.68	0.13	12	16.7%	-11.83 [-15.58, -8.08]	
Yun2019	0.31	0.1	12	1.69	0.13	12	16.8%	-11.49 [-15.13, -7.84]	
Subtotal (95% CI)			68			68	100.0%	-11.06 [-16.95, -5.17]	◆
Heterogeneity: Tau ² =	50.36; C	$hi^2 = 10$	04.22, 0	df = 5 (P -	< 0.000	01); I ²	= 95%		
Test for overall effect:	Z = 3.68	(P = 0.	0002)						
1.1.2 SD rats									
Fu 2009	204.52	35.71	10	498.07	58.32	10	42.7%	-5.81 [-8.01, -3.62]	-
Zhao 2022	35.59	9.27	10	76.41	11.32	10	57.3%	-3.78 [-5.35, -2.21]	-
Subtotal (95% CI)			20			20	100.0%	-4.65 [-6.62, -2.67]	◆
Heterogeneity: Tau ² =	1.12; Ch	$i^2 = 2.1$	8, df =	1 (P = 0.1)	14); I ² =	= 54%			
Test for overall effect:	Z = 4.62	(P < 0.	00001)						
1.1.3 db/db mice									
Tingmin 2017	456.98	55.46	12	1,144.5	81.3	12	100.0%	-9.54 [-12.60, -6.48]	
Subtotal (95% CI)			12			12	100.0%	-9.54 [-12.60, -6.48]	•
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 6.11	(P < 0.	00001)						
								-	
									-20 -10 0 10 20
Test for subgroup diff		- Side	40 46	- 2 (0 - (12 - 70	0%		ravours (experimental) Favours (Model)

Test for subgroup differences: $Chi^2 = 9.48$, df = 2 (P = 0.009), $l^2 = 78.9\%$

B. various methods of modeling

	Expe	rimenta	al	N	lodel			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.1.1 STZ=50mg									
Duan 2018	0.32	0.1	12	1.69	0.01	12	9.4%	-18.61 [-24.43, -12.80]	
Li 2018	0.32	0.09	12	1.69	0.13	12	22.7%	-11.83 [-15.58, -8.08]	
Yang2018	0.32	0.08	12	1.69	0.13	12	21.2%	-12.26 [-16.13, -8.38]	
Yun 2017	0.31	0.09	12	1.68	0.13	12	22.7%	-11.83 [-15.58, -8.08]	
Yun2019	0.31	0.1	12	1.69	0.13	12	24.0%	-11.49 [-15.13, -7.84]	
Subtotal (95% CI)			60			60	100.0%	-12.48 [-14.26, -10.69]	◆
Heterogeneity: Chi ² =	4.80, df =	= 4 (P =	0.31);	$l^2 = 17\%$					
Test for overall effect:	Z = 13.70	0 (P < 0	.0000	L)					
1.1.2 STZ>50mg									
Fu 2009	204.52	35.71	10	498.07	58.32	10	15.5%	-5.81 [-8.01, -3.62]	-
Huang 2020	48.69	7.25	8	58.55	3.77	8	54.3%	-1.61 [-2.79, -0.44]	-
Zhao 2022	35.59	9.27	10	76.41	11.32	10	30.2%	-3.78 [-5.35, -2.21]	+
Subtotal (95% CI)			28			28	100.0%	-2.92 [-3.78, -2.05]	◆
Heterogeneity: Chi ² =	12.60, df	= 2 (P	= 0.00	2); $I^2 = 8$	4%				
Test for overall effect:	Z = 6.62	(P < 0.	00001)						
									-20 -10 0 10 20
									Favours [experimental] Favours [Model]
Test for subgroup diffe	erences: C	$hi^2 = 8$	9.26, d	f = 1 (P - 1)	< 0.000	01), I ²	= 98.9%		



https://doi.org/10.1371/journal.pone.0282275.g012

90%). Through the above subgroup analyses, it was suggested that modeling methods, animal species, and duration of treatment were potential confounders that might increase the heterogeneity of outcome measures.

Consistently, the same confounding factors were revealed in another previous study with renal pathology as an experimental index [28]. We re-screened the following potential confounding factors (including evaluation and grading of the glomerular mesangial expansion index and the tubulointerstitial damage index, tissue section thickness, and periodic acid-Schiff (PAS) staining method) through subgroup analysis of the renal pathology. In the subgroup analysis of tissue section thickness, 1 of the studies was removed because it did not mention the renal tissue section thickness. The heterogeneity of the group with tissue section thickness 2 μ m (Fig 14A) (n = 48, SMD -3.17, 95% CI (-4.06, -2.27, p < 0.00001; heterogeneity: $\chi^2 = 0.15$, $I^2 = 0\%$) was substantially reduced compared with other groups (Fig 14A) (n =, 48, SMD -9.21, 95% CI (-11.30, -7.11, p < 0.00001; heterogeneity: $\chi^2 = 0.07$, $I^2 = 0$ %). In the subgroup analysis of the PAS staining method, 2 of studies were removed because they did not mention the specific method of PAS staining. Contrasting the group with potassium permanganate concentration 0.5% (Fig 14B) (n = 48, SMD -9.21, 95% CI (-11.30, -7.11, p < 0.00001; heterogeneity: $\chi^2 = 0.07$, $I^2 = 0\%$) against the two groups with potassium permanganate concentration 1%, the heterogeneity of the group with potassium permanganate concentration

	Expe	rimenta	l.	N	lodel			Std. Mean Difference	Std. Mean Difference
udy or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
.1 PF =100mg/kg	g								
an 2018	0.32	0.1	12	1.69	0.01	12	14.5%	-18.61 [-24.43, -12.80]	←
2018	0.32	0.09	12	1.69	0.13	12	16.8%	-11.83 [-15.58, -8.08]	
ng2018	0.32	0.08	12	1.69	0.13	12	16.6%	-12.26 [-16.13, -8.38]	
in 2017	0.31	0.09	12	1.68	0.13	12	16.8%	-11.83 [-15.58, -8.08]	
in2019	0.31	0.1	12	1.69	0.13	12	16.9%	-11.49 [-15.13, -7.84]	
ao 2022	35.59	9.27	10	76.41	11.32	10	18.5%	-3.78 [-5.35, -2.21]	-
btotal (95% CI)			70			70	100.0%	-11.34 [-15.92, -6.76]	
terogeneity: Tau ² = st for overall effect:	= 28.88; C : Z = 4.85	$hi^2 = 56$ (P < 0.0	00001)	= 5 (P <	0.0000	1); I ² =	91%		
1.2 PF<100mg/kg	ı i								
2009	204.52	35.71	10	498.07	58.32	10	33.4%	-5.81 [-8.01, -3.62]	
uang 2020	48.69	7.25	8	58.55	3.77	8	35.4%	-1.61 [-2.79, -0.44]	-
ngmin 2017	456.98	55.46	12	1,144.5	81.3	12	31.1%	-9.54 [-12.60, -6.48]	_
btotal (95% CI)			30			30	100.0%	-5.48 [-9.99, -0.98]	
eterogeneity: Tau ² =	= 14.57; C	$hi^2 = 28$ (P = 0.0	.98, df	= 2 (P <	0.0000	1); I ² =	93%		
est for subaroup diff	ferences: C	$Chi^2 = 3.$	19. df	= 1 (P = 9	0.07). I ²	= 68.6	5%		Favours [experimental] Favours [Model]
st for subaroup diff duration of	ferences: (treatm	Chi ² = 3. ent	19. df	= 1 (P = 9	0.07). I ²	= 68.6	5%		Favours [experimental] Favours [Model]
st for subaroup diff duration of	ferences: (treatm Expe	Chi ² = 3. ent crimenta	19. df	= 1 (P = 0	0.07). I ²	= 68.6	5% Weight	Std. Mean Difference	Favours (experimental) Favours (Model) Std. Mean Difference
st for subaroup diff	ferences: (treatm Expe Mean	Chi ² = 3. ent erimenta SD	19. df II Total	= 1 (P = 9 Mean	0.07). I ² Iodel SD	= 68.6 Total	Weight	Std. Mean Difference IV, Fixed, 95% CI	Favours [experimenta]] Favours [Model] Std. Mean Difference IV, Fixed, 95% CI
est for subaroup diff duration of udy or Subgroup 1.1 12weeks	ferences: (treatm Expe Mean	Chi ² = 3. ent erimenta	19. df II Total	= 1 (P =) Mean	0.07). I ² Iodel SD	= 68.6 Total	Weight	Std. Mean Difference IV, Fixed, 95% CI	Favours [experimental] Favours [Model] Std. Mean Difference IV, Fixed, 95% Cl
ast for subaroup diff duration of i udy or Subgroup 1.1 12weeks 1an 2018 2018	ferences: (treatm Expe Mean	Chi2 = 3. ent erimenta SD 0.1 0.09	19. df Il Total	= 1 (P = 1 Mean 1.69	0.07). I ² Iodel SD	= 68.6	9.4%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80]	Std. Mean Difference IV, Fixed, 95% Cl
at for subaroup diff duration of t udy or Subgroup 1.1 12weeks an 2018 2018 po2018	ferences: C treatm Expe Mean 0.32 0.32	Chi ² = 3. ent erimenta SD 0.1 0.09 0.08	19. df II Total	= 1 (P = 0 Mean 1.69 1.69	0.07). ² Iodel SD 0.01 0.13	= 68.6	Weight 9.4% 22.7%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-16.13, -8.38]	Std. Mean Difference IV, Fixed, 95% Cl
est for subaroup diff duration of .1.1 12weeks uan 2018 2018 	ferences: 0 treatm Expe Mean 0.32 0.32 0.32 0.31	Chi ² = 3. ent erimenta SD 0.1 0.09 0.08 0.09	19. df Il Total 12 12 12 12	= 1 (P = 1 Mean 1.69 1.69 1.69	0.07). I ² Iodel SD 0.01 0.13 0.13	= 68.6 Total 12 12 12	9.4% 22.7% 21.2% 22.7%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-16.13, -8.38] -11.83 [-15.58, -8.08]	Std. Mean Difference IV, Fixed, 95% CI
st for subaroup diff duration of f udy or Subgroup 1.1 12weeks tan 2018 2018 ng2018 n 2017 n2019	ferences: 0 treatm Expe Mean 0.32 0.32 0.32 0.31 0.31	Chi ² = 3. ent erimenta SD 0.1 0.09 0.08 0.09 0.1	19. df d Total 12 12 12 12 12 12	= 1 (P = 1 Mean 1.69 1.69 1.68 1.68	0.07). I ² lodel SD 0.01 0.13 0.13 0.13 0.13	= 68.6 Total 12 12 12 12 12 12 12	9.4% 22.7% 21.2% 22.7% 24.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-61.3], -8.38 -11.83 [-15.58, -8.08] -11.49 (-15.13, -7.84)	Std. Mean Difference IV, Fixed, 95% Cl
st for subaroup diff duration of f udy or Subgroup 1.1 12weeks uan 2018 2018 ng2018 n 2017 n2019 biotal (95% CI)	ferences: 0 treatm Expe Mean 0.32 0.32 0.32 0.31 0.31	Chi ² = 3. ent crimenta SD 0.1 0.09 0.08 0.09 0.1	19. df I Total 12 12 12 12 12 12 60	= 1 (P = 0 Mean 1.69 1.69 1.69 1.68 1.69	0.07). I ² Iodel SD 0.01 0.13 0.13 0.13 0.13	= 68.6 Total 12 12 12 12 12 12 60	9.4% 9.4% 22.7% 21.2% 22.7% 24.0% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-16.13, -8.38] -11.83 [-15.58, -8.08] -11.49 [-15.13, -7.84] -12.48 [-14.26, -10.69]	Std. Mean Difference IV, Fixed, 95% Cl
udy or Subgroup diff duration of L1 12weeks an 2018 2018 ng2018 n 2017 n2019 btotal (95% CI) terogeneity: Chi ²	ferences: 6 treatm Expe Mean 0.32 0.32 0.32 0.32 0.31 0.31 4.80, df 1	Chi ² = 3. ent erimenta SD 0.1 0.09 0.08 0.09 0.1 0.1 0.9 0.1	19. df Total 12 12 12 12 12 00 0.31);	= 1 (P = 1) Mean 1.69 1.69 1.69 1.69 1.68 1.69 1.68 1.69	0.07). I ² 10del SD 0.01 0.13 0.13 0.13 0.13	= 68.6 Total 12 12 12 12 12 12 60	Weight 9.4% 22.7% 21.2% 22.7% 24.0% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-16.13, -8.38] -11.83 [-15.58, -8.08] -11.49 [-15.13, -7.84] -12.48 [-14.26, -10.69]	Std. Mean Difference IV, Fixed, 95% Cl
est for subaroup diff duration of 11 12weeks uan 2018 2018 102018 102019 102019 105061 (95% CI) 1terogeneity: Chi ² = 1st for overall effect.	ferences: 0 treatm Expe Mean 0.32 0.32 0.32 0.32 0.31 0.31 4.80, df = : Z = 13.7	$\frac{chi^{2} = 3}{chi^{2} = 3}$ erimenta signature 0.1 0.09 0.08 0.09 0.1 = 4 (P = 0 0 (P < 0)	19. df Total 12 12 12 12 60 0.31); .00001	= 1 (P = 0) Mean 1.69 1.69 1.69 1.68 1.69 1.68 1.69 1.68 1.09 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	0.07). I ² 10del SD 0.01 0.13 0.13 0.13 0.13	Total	Weight 9.4% 22.7% 21.2% 22.7% 24.0% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-16.13, -8.38] -11.43 [-15.58, -8.08] -11.49 [-15,13, -7.84] -12.48 [-14.26, -10.69]	Std. Mean Difference IV, Fixed, 95% CI
est for subaroup diff duration of 11 12weeks uan 2018 2018 ing2018 ing2018 ing2017 ing2019 ibtotal (95% CI) terogeneity: Chi ² est for overall effect: 1.2 < 12weeks	ferences: C treatm Expe Mean 0.32 0.32 0.32 0.31 0.31 4.80, df : Z = 13.7	Chi ² = 3. ent crimenta SD 0.1 0.09 0.08 0.09 0.1 = 4 (P = 0 (P < 0	19. df Total 12 12 12 12 12 60 0.31); .00001	= 1 (P = 1) Mean 1.69 1.69 1.69 1.68 1.69 1.6 1.6 1.6 1.6 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	0.07). I ² 10del SD 0.01 0.13 0.13 0.13 0.13	= 68.6 Total 12 12 12 12 12 60	Weight 9.4% 22.7% 21.2% 22.7% 24.0% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-16.13, -8.38] -11.43 [-15.58, -8.08] -11.49 [-15.13, -7.84] -12.48 [-14.26, -10.69]	Favours [experimental] Favours [Model] Std. Mean Difference IV, Fixed, 95% CI
audy or Subgroup diff duration of udy or Subgroup 1.1 12weeks uan 2018 2018 ung2018 ung2018 ung2018 ung2018 ung2018 ung2018 ubtotal (95% CI) eterogeneity: Chi ² = est for overall effect: 1.2 <12weeks 2009	ferences: C treatm Expe Mean 0.32 0.32 0.32 0.31 0.31 4.80, df - Z = 13.7 204.52	$\begin{array}{l} \text{Chi}^2 = 3, \\ \text{ent} \\ \text{erimenta} \\ \text{SD} \\ \hline \\ 0.1 \\ 0.09 \\ 0.09 \\ 0.1 \\ = 4 \ (P = 0 \\ 0 \ (P < 0 \\ 35.71 \\ \end{array}$	19. df Total 12 12 12 12 12 12 0 0.31); .00001 10	= 1 (P = 1) Mean 1.69 1.69 1.69 1.69 1.69 1.69 1.69 1.69	0.07). I ² 10del SD 0.01 0.13 0.13 0.13 0.13 0.13 0.13	= 68.6 Total 12 12 12 12 12 12 12 12 12 12	Weight 9.4% 22.7% 21.2% 22.7% 24.0% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-61.3], -8.38 -11.83 [-15.58, -8.08] -11.49 [-15.13, -7.84] -12.48 [-14.26, -10.69] -5.81 [-8.01, -3.62]	Favours [experimental] Favours [Model] Std. Mean Difference IV, Fixed, 95% Cl
est for subaroup diff duration of 1.1 12weeks an 2018 2018 n2017 2017 n2019 Ibtotal (95% CI) tierogeneity: Chi ² = st for overall effect: 1.2 c12weeks 2009 ang 2020	ferences: C treatm Expe Mean 0.32 0.32 0.31 0.31 4.80, df i Z = 13.7 204.52 48.69	Chi ² = 3. ent erimenta SD 0.1 0.09 0.08 0.09 0.1 = 4 (P = 0 (P < 0 35.71 7.25	19. df Total 12 12 12 12 12 12 10 0.31); .00001	= 1 (P = 1) Mean 1.69 1.69 1.69 1.69 1.69 1.69 1.69 1.2 498.07 58.55	0.07). I ² 10del SD 0.01 0.13 0.13 0.13 0.13 0.13 58.32 3.77	= 68.6 Total 12 12 12 12 12 12 12 12 12 12	Weight 9.4% 22.7% 21.2% 22.7% 24.0% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -11.43 [-15.58, -8.08] -11.43 [-15.13, -7.84] -12.48 [-14.26, -10.69] -5.81 [-8.01, -3.62] -1.61 [-2.79, -0.44]	Favours [experimental] Favours [Model]
at for subaroup diff duration of udy or Subgroup 11 12weeks uan 2018 2018 ung2018 ung2018 ung2018 ung2017 ubtotal (95% CI) eterogeneity: Chi ² = st for overall effect: 12 <12weeks 12 009 uang 2020 ngmin 2017	ferences: C treatm Expe Mean 0.32 0.32 0.32 0.31 0.31 4.80, df i : Z = 13.7 204.52 4.869 456.98	Chi ² = 3. ent erimenta SD 0.1 0.09 0.08 0.09 0.1 = 4 (P = 0 (P < 0 35.71 7.25 55.46	19. df Total 12 12 12 12 12 60 0.31); .00001 10 8 12	= 1 (P = 1) Mean 1.69 1.69 1.69 1.69 1.69 1.69 1.69 1.69	0.07). I ² 10del SD 0.01 0.13 0.14	= 68.6 Total 12 12 12 12 12 12 60 10 8 12	Weight 9.4% 22.7% 21.2% 22.7% 24.0% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-61.3], -8.38] -11.83 [-15.58, -8.08] -11.49 [-15.13, -7.84] -12.48 [-14.26, -10.69] -5.81 [-8.01, -3.62] -1.61 [-2.79, -0.44] -9.54 [-12.60, -6.48]	Favours [experimental] Favours [Model]
at dy or Subgroup diff duration of in 2008 2018 uan 2018 2018 un 2017 un2019 biotal (95% CI) aterogeneity: Chi ² sis for overall effect: 1.2 < 12weeks 1.2009 aang 2020 ngmin 2017 iao 2022 biotal (95% CI)	ferences: C treatm Expe Mean 0.32 0.32 0.32 0.31 0.31 4.80, df : z = 13.7 204.52 48.69 456.98 35.59	Chi ² = 3. ent ent 0.1 0.09 0.08 0.09 0.1 = 4 (P = 0 (P < 0) 35.71 7.25 55.46 9.27	19. df 10 12 12 12 12 12 12 12 12 12 12	= 1 (P = 1) Mean 1.69 1.69 1.69 1.69 1.69 1.69 1.69 1.69	58.32 3.77 81.33 11.32	= 68.6 Total 12 12 12 12 12 60 10 8 12 10 8 12 10 40	Weight 9.4% 22.7% 21.2% 22.7% 24.0% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-61.3], -8.38] -11.28 [-15.58, -8.08] -11.49 [-51.3], -7.84] -12.48 [-14.26, -10.69] -5.61 [-8.01, -3.62] -1.61 [-2.79, -0.44] -9.54 [-12.60, -6.48] -3.78 [-5.35, -2.21] -3.41 [-4.24, -2.58]	Favours [experimental] Favours [Model]
est for subaroup diff duration of i udy or Subgroup 1.1 12weeks an 2018 2018 2018 2019 brotal (95% CI) terogeneity: Chi ² = est for overall effect 1.2 <12weeks 2009 aang 2020 angrin 2017 ao 2022 brotal (95% CI)	ferences: C treatm Expe Mean 0.32 0.32 0.32 0.31 0.31 4.80, df i : Z = 13.7 204.52 48.69 456.98 456.98 29.27, df	Chi ² = 3. ent chi ² = 3. ent chi chi chi chi chi chi chi chi chi chi	19. df Total 12 12 12 12 12 12 10 8 12 10 8 12 10 8 12 10 8 12 12 12 12 12 12 12 12 12 12	$= 1 (P = 1)$ Mean 1.69 1.69 1.69 1.69 1.69 1.69 1.69 1.68 1.69 1.2 = 17% 498.07 58.55 1.144.5 76.41 001); $l^2 = 1$	0.07). I ² lodel SD 0.01 0.13 0.13 0.13 0.13 0.13 0.13 0.13 1.132 90%	= 68.6 Total 12 12 12 12 12 12 12 10 8 12 10 40	Weight 9.4% 22.7% 21.2% 22.7% 24.0% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-16.13, -8.38] -11.43 [-15.58, -8.08] -11.43 [-15.13, -7.84] -12.48 [-14.26, -10.69] -5.81 [-8.01, -3.62] -1.61 [-2.79, -0.44] -9.54 [-12.60, -6.48] -3.78 [-5.55, -2.21] -3.41 [-4.24, -2.58]	Favours [experimental] Favours [Model]
st for subaroup diff duration of in 12weeks an 2018 2018 2018 2019 btotal (95% CI) terogeneity: Chi ² = st for overall effect: i.2 <12weeks 2009 ang 2020 agmi 2017 to 2022 btotal (95% CI) terogeneity: Chi ² = st for overall effect:	ferences: C treatm Expe Mean 0.32 0.32 0.32 0.31 4.80, df 1 : Z = 13.7 204.52 48.69 456.98 35.59 29.27, df : Z = 8.03	Chi ² = 3. ent erimenta SD 0.1 0.09 0.1 = 4 (P = 0 (P < 0) 35.71 7.25 55.46 9.27 f = 3 (P < 0.0	19. df Total 12 12 12 12 12 12 12 10 8 12 10 8 12 00 0001)	$= 1 (P = 1)^{1}$ $\frac{Mean}{1.69}$ 1.69 1	0.07). I ² 10del SD 0.01 0.13 0.13 0.13 0.13 0.13 0.13 1.132 90%	= 68.6 Total 12 12 12 12 12 12 60	Weight 9.4% 22.7% 21.2% 24.0% 100.0% 14.4% 50.3% 7.4% 27.9% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -11.83 [-15.58, -8.08] -11.49 [-15.13, -7.84] -12.48 [-14.26, -10.69] -5.81 [-8.01, -3.62] -1.61 [-2.79, -0.44] -9.54 [-12.60, -6.48] -3.78 [-5.35, -2.21] -3.41 [-4.24, -2.58]	Favours [experimental] Favours [Model]
st for subarouo diff duration of L1 12weeks an 2018 2018 n2019 btotal (95% CI) terogeneity. Chi ² = st for overall effect: L2 <12weeks 2009 ang 2020 igmin 2017 10 2022 btotal (95% CI) terogeneity. Chi ² = st for overall effect:	ferences: C treatm Expe Mean 0.32 0.32 0.32 0.31 0.31 4.80, df f : Z = 13.7 204.52 48.69 456.98 35.59 29.27, df Z = 8.03	Chi ² = 3. ent srimenta SD 0.1 0.09 0.1 = 4 (P = 0 (P < 0) 35.71 7.25 55.46 9.27 f = 3 (P < 0.0	19. df I Total 12 12 12 12 12 12 12 12 12 12	$= 1 (P = 1)^{10}$ $\frac{Mean}{1.69}$ $\frac{1.69}{1.69}$ $\frac{1.69}{1.69}$ $\frac{1.69}{1.69}$ $\frac{1}{2} = 17\%$ $\frac{498.07}{58.55}$ $\frac{1.144.55}{76.41}$ $\frac{10001}{1}; 1^{2} = 1000$	0.07), i ² 10del <u>SD</u> 0.01 0.13 0.13 0.13 0.13 0.13 1.13 2.3,77 81,3 11,32 90%	= 68.6 Total 12 12 12 12 12 12 12 12 12 12	Weight 9.4% 22.7% 21.2% 24.0% 100.0% 14.4% 50.3% 7.4% 27.9% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -11.2.26 [-16.13, -8.38] -11.48 [-15.58, -8.08] -11.48 [-15.13, -7.84] -12.48 [-14.26, -10.69] -5.81 [-8.01, -3.62] -1.61 [-2.79, -0.44] -9.54 [-12.60, -6.48] -3.78 [-5.35, -2.21] -3.41 [-4.24, -2.58]	Favours [experimental] Favours [Model]
est for subaroup diff duration of i tudy or Subgroup 1.1 12weeks uan 2018 2018 ang2018 un 2017 un2019 ubtotal (95% CI) eterogeneity: Chi ² = est for overall effect: 1.2 < 12weeks 1 2009 uang 2020 ingmin 2017 hao 2022 ubtotal (95% CI) eterogeneity: Chi ² = est for overall effect:	ferences: C treatm Expe Mean 0.32 0.32 0.31 0.31 4.80, df 4 Z = 13.7 204.52 48.69 456.98 35.59 29.27, df Z = 8.03	Chi ² = 3. ent SD 0.1 0.09 0.08 0.09 0.1 = 4 (P = 0 (P < 0) 35.71 7.25 55.46 9.27 f = 3 (P = (P < 0.0)	19. df I Total 12 12 12 12 12 12 12 12 12 12	$= 1 (P = 1)^{10}$ Mean 1.69 1.69 1.69 1.69 1.69 1.69 1.69 1.6 1.69 1.6 1.69 1.6 1.69 1.6 1.69 1.6 1.69 1.6 1.69 1.6 1.69 1.6 1.69 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	0.07), l ² 10del SD 0.01 0.13 0.13 0.13 0.13 0.13 0.13 1.132 90%	= 68.6 Total 12 12 12 12 12 12 12 12 12 12	Weight 9.4% 22.7% 21.2% 22.7% 24.0% 100.0%	Std. Mean Difference IV, Fixed, 95% CI -18.61 [-24.43, -12.80] -11.83 [-15.58, -8.08] -12.26 [-61.3], -8.38 -11.83 [-15.58, -8.08] -11.49 [-5.13, -7.84] -12.48 [-14.26, -10.69] -5.81 [-8.01, -3.62] -1.61 [-2.79, -0.44] -9.54 [-12.60, -6.48] -3.78 [-5.35, -2.21] -3.41 [-4.24, -2.58]	Std. Mean Difference IV, Fixed, 95% CI

Fig 13. Effects of PF on 24-h urinary protein in subgroups. (A) PF dose; (B) Duration of treatment.

https://doi.org/10.1371/journal.pone.0282275.g013

0.5% was greatly reduced. Through the above subgroup analyses, we considered that the tissue section thickness and the drug concentration of specific experimental procedures (e.g., PAS, HE, and Masson) might also be the potential confounding factors that increased the heterogeneity of outcome measures.

3.3.8 Hypothetical model of the protective mechanisms of PF. Based on the above literature analysis, we proposed a hypothetical model of the protective mechanisms of PF against DN. PF might exert therapeutic effects on DN through the inhibition of the TLR2/4 signaling pathway under high glucose stimulation to initiate macrophage activation. Its therapeutic effects were not only related to the regulation of inflammatory pathways (e.g., MyD88 and NFκB pathway) and inflammatory cytokines (e.g., TNF-α, IL-1β, MCP-1), but also related to the regulation of antioxidant effects (e.g., SOD and GSH-PX) (Fig 15). The possible mechanisms of PF in mediating reno-protection are summarized as follows: (1) reducing mesangial expansion index and tubulointerstitial injury index, and alleviating pathological renal injury; (2) inhibiting macrophage infiltration activation and suppressing M1 macrophage production; (3) reducing the production of inflammatory factors (TNF-α, IL-1β, MCP-1) and iNOS, a marker of macrophage activation; (4) decreasing the expression of TLR2/4 and inhibiting their downstream signaling pathways (MyD88, P-IRAK1, Trif, P-IRF3, NF-κB-p-p65, NF-κB-p65; (5) reducing p-JAK2 and p-STAT3 proteins and inhibiting JAK2/STAT3 signaling pathway activation; (6) increasing SOD and GSH-Px activity to reduce the release of MDA, inhibiting renal inflammatory responses, and improving the body peroxidation status, thus alleviating the severity of renal injury.

A. Tissue slice thickness

	Expe	erimen	tal	N	lodel			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
7.2.1 thickness≠2µn	n								
Yun 2017	1	0.14	12	2.43	0.15	12	47.1%	-9.52 [-12.57, -6.46]	_
Yun2019	1.01	0.13	12	2.41	0.17	12	52.9%	-8.93 [-11.81, -6.05]	_
Subtotal (95% CI)			24			24	100.0%	-9.21 [-11.30, -7.11]	◆
Heterogeneity: Tau ² =	= 0.00; 0	$Chi^2 = 0$	0.07, d	f = 1 (F)	P = 0.7	'8); I ² =	0%		
Test for overall effect:	Z = 8.6	52 (P <	0.000	01)					
7.2.2 thickness=2um	n								
Li 2018	1.03	0.28	12	2.46	0.51	12	46.6%	-3.36 [-4.67, -2.05]	
Yang2018	1.01	0.34	12	2.43	0.55	12	53.4%	-3.00 [-4.22, -1.77]	
Subtotal (95% CI)			24			24	100.0%	-3.17 [-4.06, -2.27]	◆
Heterogeneity: Tau ² =	= 0.00; 0	$Chi^2 = 0$	0.15, d	f = 1 (F)	P = 0.7	'0); I ² =	: 0%		
Test for overall effect:	Z = 6.9	93 (P <	0.000	01)					
									-10 -5 0 5 10
Test for subgroup diff	ferences	· Chi ² =	= 27.05	df =	1 (P <	0.000	(1) $I^2 = 0$		-10 -5 0 5 10 Favours [experimental] Favours [Model]
Test for subgroup diff	ferences	: Chi ² =	= 27.05	, df =	1 (P <	0.0000)1), I ² = 9		-10 -5 0 5 10 Favours [experimental] Favours [Model]
Test for subgroup diff	ferences meth	: Chi² = od	= 27.05	, df =	1 (P <	0.0000	01), I ² = 9	.3%	-10 -5 0 5 10 Favours [experimental] Favours [Model]
Test for subgroup diff B. PAS staining	ferences meth	: Chi ² = od	= 27.05	, df =	1 (P <	0.0000)1), I ² = 9	16.3%	-10 -5 0 5 10 Favours [experimental] Favours [Model]
Test for subgroup diff PAS staining	ferences metho Expe	: Chi ² = od erimen	= 27.05 tal	, df = Mean	1 (P < Model	0.0000)1), I ² = 9	16.3% Std. Mean Difference IV. Bandom, 95% Cl	-10 -5 0 5 10 Favours [experimental] Favours [Model] Std. Mean Difference
Test for subgroup diff B. PAS staining Study or Subgroup 7.2.1 PAS staining:0.	ferences metho Expe Mean	Chi ² = od erimen SD 04	= 27.05 tal Total	, df = Mean	1 (P < Model SD	0.0000 Total	01), I ² = 9 Weight	6.3% Std. Mean Difference IV, Random, 95% CI	-10 -5 0 5 10 Favours [experimental] Favours [Model] Std. Mean Difference IV, Random, 95% Cl
Test for subgroup diff B. PAS staining Study or Subgroup 7.2.1 PAS staining:0. Yun 2017	ferences methe Expe Mean .5%KMn	: Chi ² = od erimen SD 04	= 27.05 tal Total	, df = Mean	1 (P < Model SD	0.0000 Total	01), I ² = 9 Weight	6.3% Std. Mean Difference IV, Random, 95% CI	-10 -5 5 10 Favours [experimental] Favours [Model] Std. Mean Difference IV, Random, 95% CI
Test for subgroup diff B. PAS staining Study or Subgroup 7.2.1 PAS staining:0. Yun 2017 Yun 2019	ferences methe Expe Mean .5%KMn 1	: Chi ² = od erimen SD 04 0.14	= 27.05 tal Total	, df = <u>Mean</u> 2.43 2.41	1 (P < Model SD 0.15 0.17	0.0000	 Weight 47.1% 52.9% 	16.3% Std. Mean Difference IV, Random, 95% CI -9.52 [-12.57, -6.46] -8.93 [-13] 1 = 6 051	Std. Mean Difference
Test for subgroup diff B. PAS staining Study or Subgroup 7.2.1 PAS staining:0. Yun 2017 Yun2017 Yun2019 Subtotal (95% Cl)	ferences metho Expe Mean .5%KMn 1 1.01	: Chi ² = od erimen SD 04 0.14 0.13	= 27.05 tal Total 12 12 24	, df = Mean 2.43 2.41	1 (P < Model SD 0.15 0.17	0.0000 Total 12 12 24	Weight 47.1% 52.9% 100.0%	5td. Mean Difference IV, Random, 95% CI -9.52 [-12.57, -6.46] -8.93 [-11.81, -6.05] -9.21 [-11.30, -7.11]	Favours [experimental] Favours [Model]
Test for subgroup diff 3. PAS staining <u>Study or Subgroup</u> 7.2.1 PAS staining:0. Yun 2017 Yun2019 Subtotal (95% CI) Heterogeneity: Tau ²	ferences metho Expe Mean .5%KMni 1.01	: Chi ² = od erimen SD 04 0.14 0.13 Chi ² =	= 27.05 tal Total 12 12 24 0.07, d	, df = Mean 2.43 2.41 f = 1 (1	1 (P < Model SD 0.15 0.17 P = 0.7	0.0000 Total 12 12 24 78): 1 ² =	Weight 47.1% 52.9% 100.0%	6.3% Std. Mean Difference IV, Random, 95% CI -9.52 [-12.57, -6.46] -8.93 [-11.81, -6.05] -9.21 [-11.30, -7.11]	Std. Mean Difference IV, Random, 95% Cl
Test for subgroup diff 3. PAS staining <u>Study or Subgroup</u> 7.2.1 PAS staining:0. Yun 2017 Yun2019 Subtotal (95% Cl) Heterogeneity: Tau ² Test for overall effect:	ferences metho 5%KMn 1 1.01 = 0.00; 0 : Z = 8.6	: Chi ² = od erimen <u>SD</u> 04 0.14 0.13 Chi ² = 52 (P <	= 27.05 tal Total 12 12 24 0.07, d : 0.000	, df = Mean 2.43 2.41 f = 1 (1 01)	1 (P < Model SD 0.15 0.17 P = 0.7	0.0000 Total 12 12 24 78); I ² =	Weight 47.1% 52.9% 100.0%	6.3% Std. Mean Difference IV, Random, 95% CI -9.52 [-12.57, -6.46] -8.93 [-11.81, -6.05] -9.21 [-11.30, -7.11]	Std. Mean Difference IV, Random, 95% CI
Test for subgroup diff 3. PAS staining Study or Subgroup 7.2.1 PAS staining:0. Yun 2017 Yun2019 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 7.2.2 PAS ctaining:1	ferences metho Expe Mean .5%KMni 1 1.01 = 0.00; (: Z = 8.6	: Chi ² = od erimen <u>SD</u> 04 0.14 0.13 Chi ² = 52 (P <	= 27.05 tal Total 12 12 24 0.07, d : 0.000	, df = <u>Mean</u> 2.43 2.41 f = 1 (0 01)	1 (P < Model SD 0.15 0.17 P = 0.7	0.0000 Total 12 12 24 78); I ² =	Weight 47.1% 52.9% 100.0%	16.3% Std. Mean Difference IV, Random, 95% CI -9.52 [-12.57, -6.46] -8.93 [-11.81, -6.05] -9.21 [-11.30, -7.11]	Std. Mean Difference IV, Random, 95% Cl
Test for subgroup diff 3. PAS staining Study or Subgroup 7.2.1 PAS staining:0. Yun 2017 Yun 2019 Subtotal (55% CI) Heterogeneity: Tau ² = Test for overall effect: 7.2.2 PAS staining:1 Yun2018	ferences meth Expe Mean 1,01 = 0.00; 0 : Z = 8.6 %KMn0 4	: Chi ² = od erimen SD 04 0.14 0.13 Chi ² = 52 (P <	= 27.05 tal 12 12 24 0.07, d : 0.000	, df = <u>Mean</u> 2.43 2.41 f = 1 (0 01)	1 (P < Model SD 0.15 0.17 P = 0.7	0.0000 Total 12 12 24 78); I ² =	Weight 47.1% 52.9% 100.0%	5td. Mean Difference IV, Random, 95% Cl -9.52 [-12.57, -6.46] -8.93 [-11.81, -6.05] -9.21 [-11.30, -7.11]	Std. Mean Difference IV, Random, 95% Ci

Test for subgroup differences: $Chi^2 = 25.17$, df = 1 (P < 0.00001), $I^2 = 96.0\%$



https://doi.org/10.1371/journal.pone.0282275.g014

4. Discussion

Heterogeneity: Not applicable

Test for overall effect: Z = 4.80 (P < 0.00001)

4.1 Summary of evidence

This is the first preclinical systematic review to evaluate the efficacy of PF in animal DN models, including 9 studies with 526 animals. Generally, the included studies are of medium quality. Our analysis results suggest that PF is a multifaceted reno-protective agent for the treatment of DN.

-i0

Favours [experimental] Favours [Model]

4.2 Possible mechanisms

4.2.1 Inhibition of macrophage infiltration and activation. Abnormal macrophage infiltration, recruitment, and activation can be commonly observed in the renal tissues of DN patients and animal DN models, leading to renal immunoinflammatory injury [29]. Activated macrophages can damage renal tissues through the release of inflammatory factors. For example, monocyte macrophages can release proteolytic enzymes and reactive oxygen species clusters that cause glomerular injury, structural remodeling, sclerosis, tubular atrophy, interstitial inflammation, and fibrosis [30].

Ricardo et al. have found that macrophages can be activated into different subtypes under different microenvironments: classically activated (M1-type) and alternatively activated (M2-type), respectively [31]. M1 macrophages promote inflammatory responses and tissue damage [32]. Studies have confirmed that iNOS is one of the marker products of M1 pheno-type [33]. The synthesis of iNOS can promote nitric oxide to bind superoxide anion and produce some hydroxyl radical superoxide, thus affecting cell membrane permeability and initiating metabolic abnormalities [34]. Kawagoe et al. have observed an increasing trend in CD68 protein level and MCP-1 mRNA expression in an STZ-induced diabetes model [35].

10



Fig 15. Hypothetical mechanism of the reno-protective effect of PF against DN.

https://doi.org/10.1371/journal.pone.0282275.g015

CD68 is a typical macrophage surface marker protein, which can be used to judge the therapeutic efficacy [36]. MCP-1 can induce fibrocyte proliferation and accelerate glomerulosclerosis to tubulointerstitial transition, gradually leading to the deterioration of renal function [37, 38].

Reducing macrophage infiltration in renal tissues can obviously improve renal function. In STZ-induced rats, CCR2 antagonist can significantly alleviate macrophage infiltration, reduce urinary protein contents, and restore renal function [39]. In our study, PF inhibited macrophage infiltration and reduced the release of active products after macrophage activation, showing obvious anti-inflammatory and immunomodulatory effects.

4.2.2 Regulation of inflammatory changes. Inflammatory response plays an important role in the pathogenesis of DN. Various inflammatory mediators and chemokines influence the progression of DN and contribute to kidney injury [40]. In addition to macrophage infiltration, the role of the TLRs family in the inflammatory mechanism of DN has received wide concerns, especially TLR2 and TLR4 [41, 42] NF- κ B can be activated by high glucose, and the presence of NF- κ B signaling pathway activation has been observed in peripheral blood mononuclear cells of DN patients [43]. The activation of NF- κ B is a marker of renal injury and an important etiological factor of urinary protein in DN patients [44].

Recent studies have found that janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathways are also closely related to the development of DN [45]. JAK2/ STAT3 gene expression is significantly elevated in DN patients [46]. Activation of the JAK/ STAT pathway promotes mesangial cell proliferation and accelerate macrophage infiltration, leading to kidney injury. Experimental results in cultured human mesangial cells have shown that inhibitors of cell signaling pathways can suppress JAK2/STAT3 pathway activation and reduce the corresponding gene expression [47]. Marrero et al., have shown in STZ-induced diabetic rats that AG490 intervention treatment can significantly inhibit glomerular JAK2 and STAT3 phosphorylation, manifesting as a reduction in albuminuria along with a predominance of blood pressure reduction [48]. Our study showed that PF could inhibit the proteins downstream of TLR2/4 and JAK2/STAT3 signaling pathways including MyD88, p-IRAK-1, NF- κ B-p-p65, Trif, and p-IRF3, and also reduce the expressions of macrophage inflammatory factors including TNF- α , MCP-1, IL-1 β , and iNOS.

4.2.3 Promotion of antioxidant status. Oxidative stress plays a prominent role in the pathogenesis and pathophysiology of DN. A persistent high glucose state may weaken the antioxidant capacity, induce the production of inflammatory factors and reactive oxygen species, and cause damage to the cell structure, further aggravating renal impairment [49]. Oxidative stress is primarily due to the imbalance between oxidants and antioxidants. The degree of imbalance is mainly reflected by GSH-Px, SOD, and MDA [50]. SOD, an endogenous scavenger of oxygen free radicals, contributes to maintaining the antioxidant capacity of the body; GSH-Px can scavenge toxic peroxides in vivo, block free radical damage, and maintain the intracellular redox state [50]. MDA is the product of lipid peroxidation in the body, and the content of MDA can reflect the degree of body oxidative damage [51]. GSH inhibits oxidative stress and abnormal angiogenesis by targeting multiple factors and improving cellular immune responses in DN patients [52].

The study suggested that PF could inhibit renal inflammatory responses and improve the peroxidation status in DN rats via the SIRT1/Nrf2 signaling pathway, thereby alleviating the degree of renal tissue injury and exerting reno-protective effects. SIRT1, a class of histone deacetylases, can regulate oxidative stress, inflammatory response, apoptosis, and many other physiopathological activities [53]. Nrf2 is a core transcription factor that regulates endogenous antioxidant pathways and is bound in the cytoplasm by kelch propylene oxide related protein 1 (Keap1) in the resting state. Activated SIRT1 can change the conformation of Keap1, allowing Nrf2 to dissociate from it, translocate into the nucleus, and become activated. Subsequently, activated Nrf2 can regulate antioxidant pathways and improve the antioxidant capacity of tissues and cells, thereby alleviating the degree of renal oxidative stress [54]. PF potentially regulated the SIRT1/Nrf2/NF- κ B signaling pathways to upregulate GSH-Px and SOD indicators, thereby attenuating renal oxidative stress.

4.3 Implications

STZ is a highly selective islet β cytotoxic agent that typically administered as a single high dose, resulting in complete β cell necrosis. Different animals have different sensitivity to STZ. C57BL/6 mice, like Wistar and SD rats, are exquisitely sensitive to STZ [55]. In fact, since the body size of rats facilitates the access to adequate renal tissues for monitoring renal physiological cases, studies are more inclined to select rats to establish diabetes models. STZ dose is one of the most important factors determining whether the DN model is successfully established [56]. STZ at low doses may not successfully induce the expected diabetes model, while high doses (≥ 65 mg/kg) may cause death, nephrotoxicity, or acute tubular necrosis in animals [57, 58]. It is reported that STZ at a dose of 55 mg/kg can significantly avoid the above side responses in rats [59]. Our subgroup analysis of STZ dose showed a significant difference in the 24-h urinary protein between the > 50 mg/kg STZ group and the ≤ 50 mg/kg STZ group, which may be due to that the relatively high doses of STZ (≥ 50 mg/kg) caused nephrotoxicity, rather than hyperglycemia, thus affecting the 24-h urinary protein. Since different types of mice are highly sensitive to STZ, the dosage of STZ should be strictly controlled to avoid high

animal mortality and solve the problem of low modeling rate. (1) The protocol employed multiple administrations of low-dose STZ to model pathological outcomes similar to human T1DM with insulitis and insulin deficiency. (2) Animals exposed to a high-fat diet were given an intermediate dose of STZ to reduce the β cell capacity and, as a result, induce hyperglycemia associated with insulin resistance [59, 60]. (3) The suitable temperature and humidity were guaranteed throughout the modeling process. The animals had free access to food and water before STZ injection, and then the mice had to fast for 4 h and 6–8 h, etc.

Although no obvious difference was found in the treatment duration between the highdose PF group (100 mg/kg) and the low-dose PF group (60 mg/kg), our subgroup analysis of the effect of PF treatment duration on 24-h urinary protein showed a clear difference between the group with 12 weeks of treatment (n = 120, SMD-16.38, 95% CI (-23.78, -8.99, p < 0.00001; heterogeneity: $\chi^2 = 58.56$, $I^2 = 93\%$) and the group with < 12 weeks of treatment (n = 44, SMD-0.02, 95% CI (-0.61, 0.57, p = 0.94; heterogeneity: $\chi^2 = 0$, $I^2 = 0$ %), suggesting that PF treatment duration was most likely to be the source of heterogeneity. The heterogeneity produced by the length of oral PF exposure may be related to the absorption of PF in the body or the pharmacokinetics of the receptor binding. Numerous pharmacokinetic studies have shown that PF has a low bioavailability low. The bioavailability of PF is around 3% to 4% in rats after oral administration [61, 62], which may be related to the low penetration rate and metabolic pathway of PF. Lipophilicity and p-glycoprotein-mediated efflux can affect the penetration rate of PF in vivo. The metabolic pathways of PF are mainly the hydrolysis of ester bonds, glycosidic bonds, and the conjugation with glucuronic acid [63, 64]. PF is not metabolized by intestinal mucosal enzymes in the intestinal wall, and its degradation rate is also extremely low in the liver and lung [62]. In addition, oral bioavailability is a key factor to ensure that effective drug concentrations are achieved [65]. The low bioavailability of PF limits its clinical application due to its high hydrophilicity and low lipophilicity, low permeability, transporter efflux, and hydrolytic degradation in the intestinal lumen. The present study is still in the phase of exploring whether the drug is effective or not. The results suggest that PF suppresses the immune and restores renal functions in DN. However, the differential relationship between high and low PF doses and efficacy remains uncertain, which may be related to the low bioavailability of PF. Therefore, (1) we suggest to explore approaches to promote PF bioavailability and determine the optimal dosage and therapeutic time frame of PF in DN so as to expand the application of PF in the clinic. Accumulating evidence has confirmed that esterification of hydrophilic compounds can modulate the affinity of PF [66, 67]. (2) Blocking efflux transporters can increase the bioavailability of PF, perhaps by using glucosidase inhibitors. (3) In addition, paeoniflorin-6'-o-benzene sulfonate (cp-25) has been reported to possess a higher bioavailability as a derivative of PF. Cp-25 exhibits a favorable absorption profile, low clearance, long mean residence time, and moderate in vivo bioavailability in rats [68].

4.4 Limitations

This meta-analysis has some limitations. (1) the 9 studies included did not report blind induction of models and had flaws in both blind assessment of outcomes and sample size calculation [69]. The arrival guidelines shall be strictly followed for sample size estimation and blind assessment of outcomes in future animal studies. (2) There was a lack of relevant adverse PF outcomes, which may lead to an overestimation of the true effect of PF [70]. (3) The development of DN is often accompanied by comorbidities such as hypertension and hyperglycemia [71]. However, the factors related to hypertension and hyperglycemia were not included in 8 animal models out of 9 studies, which may bias the effectiveness of PF for DN treatment. In future animal studies, the effects caused by multiple factors should be comprehensively considered to minimize the possibility of bias. (4) In the absence of active intervention, DN will progress to ESRD within 6~7 years. The decline rate of renal function varies among DN patients and is influenced by albuminuria, blood pressure, and BG [72, 73]. The models in the 9 studies were all early DN models, 2~3 of which focused on the ability of PF to effectively reduce BUN and Scr and improve the renal function-related clinical indicators. However, it does not mean that the performance of PF treatment is effective throughout DN development. It is necessary to design more rigorous experiments to verify the value of PF in treating different stages of DN.

5. Conclusion

The present study demonstrate that PF exerts reno-protective effects in animal models of DN by promoting antioxidant effects, inhibiting macrophage infiltration activation, suppressing inflammatory responses, reducing mesangial cell proliferation, inhibiting endothelial proliferation, attenuating mesangial expansion and tubulointerstitial injury, and inhibiting TLR2 / 4 signaling pathway activation. As there are few negative reports of PF in the included studies, coupled with methodological flaws, the conclusion of benefit should be taken with caution. Follow-up studies according to the arrival guidelines are recommended. Since different types of mice are highly sensitive to STZ, it is recommended to strictly control the dosage of STZ to avoid high animal mortality and solve the problem of low modeling rate. Because of the low bioavailability of PF, further studies on renal histology in animals are urgently needed. It is recommended to actively explore the optimal dosage and therapeutic time frame of PF in the clinic and animals. Moreover, it is necessary to explore methods to improve the PF bioavailability to expand the application of PF in the clinic. In conclusion, our findings suggest that PF is a reno-protective candidate for the treatment of DN.

Supporting information

S1 Checklist. (DOCX) S1 File.

(DOCX)

Acknowledgments

The authors thank Professor Jing Guo, Jin-Hao Zeng and Dr Bo Qu for helpful comments and suggestions on the review.

Author Contributions

Conceptualization: Xue-Er Zhang, Shuang-Yuan Hu.

Data curation: Yao-bin Pang, Qu Bo, Ju-Yi Xiang, Xiao-Mei Zhang, An-Jing Chen, Jing Guo.

Formal analysis: Yao-bin Pang, Qu Bo, Ju-Yi Xiang, Jin-Hao Zeng.

Funding acquisition: Jin-Hao Zeng, Jing Guo.

Investigation: An-Jing Chen.

Methodology: Shuang-Yuan Hu, Zheng-Ru Yang, Xiao Ma.

Project administration: Xiao-Mei Zhang.

Resources: Qu Bo, Zheng-Ru Yang, Xiao-Mei Zhang.

Supervision: Xiao Ma.

Writing - original draft: Xue-Er Zhang, Yao-bin Pang, Jing Guo.

Writing - review & editing: Xue-Er Zhang, Jin-Hao Zeng, Xiao Ma, Jing Guo.

References

- Tziomalos K, Athyros VG. Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. Rev Diabet Stud RDS. 2015; 12: 110. https://doi.org/10.1900/RDS.2015.12.110 PMID: 26676664
- Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol CJASN. 2017; 12: 2032. https://doi.org/10.2215/CJN.11491116 PMID: 28522654
- Kolatsi-Joannou M, Osborn D. A Technique for Studying Glomerular Filtration Integrity in the Zebrafish Pronephros. Methods in molecular biology (Clifton, NJ). 2020. pp. 25–39. https://doi.org/10.1007/978-1-4939-9841-8_3 PMID: 31701443
- Yun J, Ren J, Liu Y, Dai L, Song L, Ma X, et al. Circ-ACTR2 aggravates the high glucose-induced cell dysfunction of human renal mesangial cells through mediating the miR-205-5p/HMGA2 axis in diabetic nephropathy. Diabetol Metab Syndr. 2021. <u>https://doi.org/10.1186/s13098-021-00692-x</u> PMID: 34174955
- Sun X, Wang P, Yao L, Wang W, Gao Y-M, Zhang J, et al. Paeonol alleviated acute alcohol-induced liver injury via SIRT1/Nrf2/NF-kB signaling pathway. Environ Toxicol Pharmacol. 2018. <u>https://doi.org/ 10.1016/j.etap.2018.04.016</u> PMID: 29704732
- Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes. 1994; 43: 649–655. https://doi.org/10.2337/diab.43.5.649 PMID: 8168641
- Kramer H, Boucher RE, Leehey D, Fried L, Wei G, Greene T, et al. Increasing Mortality in Adults With Diabetes and Low Estimated Glomerular Filtration Rate in the Absence of Albuminuria. Diabetes Care. 2018; 41: 775–781. https://doi.org/10.2337/dc17-1954 PMID: 29436384
- Zhang L-L, Wei W, Wang N-P, Wang Q-T, Chen J-Y, Chen Y, et al. Paeoniflorin suppresses inflammatory mediator production and regulates G protein-coupled signaling in fibroblast–like synoviocytes of collagen induced arthritic rats. Inflamm Res. 2008; 57: 388–395. https://doi.org/10.1007/s00011-007-7240-x PMID: 18787778
- Zhang L, Wei W. Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony. Pharmacol Ther. 2020; 207: 107452. <u>https://doi.org/10.1016/j.pharmthera.2019.107452</u> PMID: 31836457
- Chen Z, Li X-P, Li Z-J, Xu L, Li X-M. Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Int Immunopharmacol. 2013; 15: 474–477. https://doi.org/10.1016/j.intimp.2013.01.021 PMID: 23415907
- Chang Y, Zhang L, Wang C, Jia X-Y, Wei W. Paeoniflorin inhibits function of synoviocytes pretreated by rIL-1α and regulates EP4 receptor expression. J Ethnopharmacol. 2011; 137: 1275–1282. <u>https://doi.org/10.1016/j.jep.2011.07.057</u> PMID: 21840386
- Huang D, Li Z, Chen Y, Fan Y, Yu T. Paeoniflorin reduces the inflammatory response of THP-1 cells by up-regulating microRNA-124: Paeoniflorin reduces the inflammatory response of THP-1 cells through microRNA-124. Genes Genomics. 2021; 43: 623–631. <u>https://doi.org/10.1007/s13258-021-01083-2</u> PMID: 33779948
- Yang H, Song L, Sun B, Chu D, Yang L, Li M, et al. Modulation of macrophages by a paeoniflorin-loaded hyaluronic acid-based hydrogel promotes diabetic wound healing. Mater Today Bio. 2021; 12: 100139. https://doi.org/10.1016/j.mtbio.2021.100139 PMID: 34632363
- Shao Y-X, Xu X-X, Li Y-Y, Qi X-M, Wang K, Wu Y-G, et al. Paeoniflorin inhibits high glucose-induced macrophage activation through TLR2-dependent signal pathways. J Ethnopharmacol. 2016; 193: 377– 386. https://doi.org/10.1016/j.jep.2016.08.035 PMID: 27566204
- Huang Y, Wang J, Yang L, Yue L, Zhang L, Zhang Y, et al. Paeoniflorin ameliorates glycemic variabilityinduced oxidative stress and platelet activation in HUVECs and DM rats. RSC Adv. 2020. <u>https://doi.org/10.1039/d0ra02036b</u> PMID: 35692727
- Wang X, Jiang L, Liu X, Huang Y, Wang A, Zeng H, et al. Paeoniflorin binds to VEGFR2 to restore autophagy and inhibit apoptosis for podocyte protection in diabetic kidney disease through PI3K-AKT signaling pathway. Phytomedicine. 2022; 106: 154400. https://doi.org/10.1016/j.phymed.2022.154400 PMID: 36049428

- Mr M, T O, Dw H, Ga D. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004;35. https://doi.org/10.1161/01.STR.0000125719.25853.20 PMID: 15060322
- Shao Y, Xu X, Wang K, Qi X, Wu Y. Paeoniflorin attenuates incipient diabetic nephropathy in streptozotocin-induced mice by the suppression of the Toll-like receptor-2 signaling pathway. Drug Des Devel Ther. 2017;Volume 11: 3221–3233. https://doi.org/10.2147/DDDT.S149504 PMID: 29184392
- Shao Y, Gong Q, Qi X-M, Wang K, Wu Y. Paeoniflorin Ameliorates Macrophage Infiltration and Activation by Inhibiting the TLR4 Signaling Pathway in Diabetic Nephropathy. Front Pharmacol. 2019; 10: 566. https://doi.org/10.3389/fphar.2019.00566 PMID: 31191309
- Li X, Wang Y, Wang K, Wu Y. Renal protective effect of Paeoniflorin by inhibition of JAK2/ STAT3 signaling pathway in diabetic mice. Biosci Trends.: 2018 May 13; 12:168–176. <u>https://doi.org/10.5582/bst.</u> 2018.01009 PMID: 29669962
- Fu J, Li Y, Wang L, Gao B, Zhang N, Ji Q. Paeoniflorin Prevents Diabetic Nephropathy in Rats. Comp Med. 2009; 59: 557–566. PMID: 20034431; PMCID: PMC2798846.
- A Q,Huang. 2020.Effect of 6'-Phenylsulfonylpaeoniflorin on renal injury in type 2 diabetic nephropathy miceandits mechanism,master,ANHUIMEDICALUNIVERSITY.https://kns.cnki.net/KCMS/detail/detail. aspx?dbcode=CMFD&dbname=CMFD202101&filename=1021535546.nh&v=.
- ZHAO H., LI Y., ZHANG J., CHEN J., TAO Y., WANG W. 2022. Protective Effect and Mechanism of Paeoniflorin on Kidney of Diabetic Nephropathy Rats, China Pharmaceuticals. 31(1), 31–35. https://doi.org/10.3969/j.issn.1006-4931.2022.03.009.
- Duan F., Yang W., Shao Y., Wu Y. 2018. Regulation of paeoniflorin on TLR2 signaling pathway in renal tissue of diabetic mice, Acta Universitatis Medicinalis Anhu. 53. 1252–1259. <u>https://doi.org/10.19405/j.</u> cnki.issn1000-1492.2018.08.019.
- Yang J. (2018).Molecular Mechanism of Activation of Macrophage Inhibied by Peaoniflorin According to JAK2/STAT3 Signal Transductionin DiabeticKidney, doctor,ANHUIMEDICALUNIVERSITY.<u>https://kns. cnki.net/KCMS/detail/dtail.aspx?dbcode=CDFD&dbname=CDFDLAST2019&filename=1019019365.</u> nh&v=.
- Zhang T, Zhu Q, Shao Y, Wang K, Wu Y. Paeoniflorin prevents TLR2/4-mediated inflammation in type 2 diabetic nephropathy. Biosci Trends. 2017; 11: 308–318. <u>https://doi.org/10.5582/bst.2017.01104</u> PMID: 28626209
- Moriya T, Tanaka K, Hosaka T, Hirasawa Y, Fujita Y. Renal structure as an indicator for development of albuminuria in normo- and microalbuminuric type 2 diabetic patients. Diabetes Res Clin Pract. 2008; 82: 298–304. https://doi.org/10.1016/j.diabres.2008.08.015 PMID: 19004516
- H W, Z Z, Yy H, Zz Z, Y J, Hy Y, et al. Protective Effect and Possible Mechanisms of Astragaloside IV in Animal Models of Diabetic Nephropathy: A Preclinical Systematic Review and Meta-Analysis. Front Pharmacol. 2020;11. https://doi.org/10.3389/fphar.2020.00988 PMID: 32695006
- You H, Gao T, Cooper T, Reeves WB, Awad A. Macrophages directly mediate diabetic renal injury. Am J Physiol Renal Physiol. 2013. https://doi.org/10.1152/ajprenal.00141.2013 PMID: 24173355
- Chow F, Nikolic-Paterson D, Atkins R, Tesch G. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc— Eur Ren Assoc. 2004. https://doi.org/10.1093/ndt/gfh441 PMID: 15574996
- Ricardo S, Goor H van, Eddy A. Macrophage diversity in renal injury and repair. J Clin Invest. 2008. https://doi.org/10.1172/JCI36150 PMID: 18982158
- Chow F, Ozols E, Nikolic-Paterson D, Atkins R, Tesch G. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004. https://doi. org/10.1111/j.1523-1755.2004.00367.x PMID: 14675042
- Purwata TE. High TNF-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy. J Pain Res. 2011. https://doi.org/10.2147/JPR.S21751 PMID: 21811392
- 34. Kawagoe T, Takeuchi O, Takabatake Y, Kato H, Isaka Y, Tsujimura T, et al. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. 2009. Available: https://www.semanticscholar.org/paper/TANK-is-a-negative-regulator-of-Toll-like-receptor-Kawagoe-Takeuchi/0788a5c06ec98918b3851b4a3222f4db0cb900c9
- Kawagoe T., Takeuchi O., Takabatake Y. et al. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol 10, 965–972 (2009). https:// doi.org/10.1038/ni.1771 PMID: 19668221
- Yang F, Wei Y, Han D, Li Y, Shi S, Jiao D, et al. Interaction with CD68 and Regulation of GAS6 Expression by Endosialin in Fibroblasts Drives Recruitment and Polarization of Macrophages in Hepatocellular Carcinoma. Cancer Res. 2020. https://doi.org/10.1158/0008-5472.CAN-19-2691 PMID: 32591411

- Jia X, Du Y, Mao D, Wang Z, He Z, Qiu J, et al. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages. Oncotarget. 2015. https:// doi.org/10.18632/oncotarget.4658 PMID: 26305552
- Tilak P, Khashim Z, Kumpatla S, Babu M, Viswanathan V. Clinical significance of urinary Monocyte Chemoattractant Protein-1 (uMCP-1) in Indian type 2 diabetic patients at different stages of diabetic nephropathy. 2010. https://doi.org/10.1016/J.IJDM.2009.10.003
- Awad A, Kinsey GR, Khutsishvili K, Gao T, Bolton WK, Okusa M. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am J Physiol Renal Physiol. 2011. https://doi.org/10. 1152/ajprenal.00332.2011 PMID: 21880831
- 40. Gnudi L, Coward R, Long D. Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms. Trends Endocrinol Metab. 2016. https://doi.org/10.1016/j.tem.2016.07.002 PMID: 27470431
- Hassan HM, Mahran Y, Ghanim AMH. Ganoderma lucidum ameliorates the diabetic nephropathy via down-regulatory effect on TGFβ-1 and TLR-4/NFκB signalling pathways. J Pharm Pharmacol. 2021. https://doi.org/10.1093/jpp/rgab058 PMID: 33847358
- 42. Dasu M, Devaraj S, Zhao L, Hwang D, Jialal I. High Glucose Induces Toll-Like Receptor Expression in Human Monocytes. Diabetes. 2008. https://doi.org/10.2337/db08-0564 PMID: 18650365
- Navarro-González J, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol JASN. 2008. https://doi.org/10.1681/ASN.2007091048 PMID: 18256353
- 44. Thoma A, Lightfoot AP. NF-kB and Inflammatory Cytokine Signalling: Role in Skeletal Muscle Atrophy. Adv Exp Med Biol. 2018. https://doi.org/10.1007/978-981-13-1435-3_12 PMID: 30390256
- 45. Kang Y. Recent Therapies for Diabetic Nephropathy. 2016. https://doi.org/10.3904/KJM.2016.90.5.402
- Brosius F, Alpers C. New targets for treatment of diabetic nephropathy: what we have learned from animal models. Curr Opin Nephrol Hypertens. 2013. https://doi.org/10.1097/MNH.0b013e32835b3766
 PMID: 23207723
- Chen D, Liu Y, Chen J, Lin H, Guo H, Wu Y, et al. JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes. Eur J Pharmacol. 2021; 902: 174121. https://doi.org/ 10.1016/j.ejphar.2021.174121 PMID: 33901462
- Al Hroob AM, Abukhalil MH, Alghonmeen RD, Mahmoud AM. Ginger alleviates hyperglycemia-induced oxidative stress, inflammation and apoptosis and protects rats against diabetic nephropathy. Biomed Pharmacother. 2018; 106: 381–389. https://doi.org/10.1016/j.biopha.2018.06.148 PMID: 29966984
- 49. Li Z, Deng H, Guo X, Yan S, Lu C, Zhao Z, et al. Effective dose/duration of natural flavonoid quercetin for treatment of diabetic nephropathy: A systematic review and meta-analysis of rodent data. Phytomedicine. 2022; 105: 154348. https://doi.org/10.1016/j.phymed.2022.154348 PMID: 35908521
- 50. Goc Z, Szaroma W, Kapusta E, Dziubek K. Protective effects of melatonin on the activity of SOD, CAT, GSH-Px and GSH content in organs of mice after administration of SNP. Chin J Physiol. 2017. <u>https://doi.org/10.4077/CJP.2017.BAF435 PMID: 28052641</u>
- Samarghandian S, Azimi-Nezhad M, Farkhondeh T, Samini F. Anti-oxidative effects of curcumin on immobilization-induced oxidative stress in rat brain, liver and kidney. Biomed Pharmacother Biomedecine Pharmacother. 2017. https://doi.org/10.1016/j.biopha.2016.12.105 PMID: 28061405
- Zuo M, Tang J, Xiang M, Long Q, Dai J, Yu G-D, et al. Clinical observation of the reduced glutathione in the treatment of diabetic chronic kidney disease. J Cell Biochem. 2018. <u>https://doi.org/10.1002/jcb.</u> 28135 PMID: 30556156
- Strycharz J, Rygielska Ż, Świderska E, Drzewoski J, Szemraj J, Szmigiero L, et al. SIRT1 as a Therapeutic Target in Diabetic Complications. Curr Med Chem. 2018. https://doi.org/10.2174/ 0929867324666171107103114 PMID: 29110598
- Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018. <u>https://doi.org/10.1016/j.bbamcr.2018.02.010</u> PMID: 29499228
- 55. Rossini AA. Genetic Influence of the Streptozotocin-induced Insulitis and Hypergiycemia. 2:5.
- Furman BL. Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr Protoc. 2021;1. <u>https://doi.org/10.1002/cpz1.78 PMID: 33905609</u>
- 57. Tay Y-C, Wang Y, Kairaitis L, Rangan GK, Zhang C, Harris DCH. Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney Int. 2005; 68: 391–398. https://doi.org/10. 1111/j.1523-1755.2005.00405.x PMID: 15954931
- Af B, Lc Y. Streptozotocin induced diabetic nephropathy and renal tumors in the rat. Experientia. 1982;38. https://doi.org/10.1007/BF01944569 PMID: 6459954

- Chao P-C, Li Y, Chang C-H, Shieh JP, Cheng J-T, Cheng K-C. Investigation of insulin resistance in the popularly used four rat models of type-2 diabetes. Biomed Pharmacother. 2018; 101: 155–161. <u>https:// doi.org/10.1016/j.biopha.2018.02.084</u> PMID: 29486333
- Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, et al. A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat. Metabolism. 2000; 49: 1390–1394. <u>https://doi.org/10. 1053/meta.2000.17721</u> PMID: 11092499
- Takeda S, Isono T, Wakui Y, Mizuhara Y, Amagaya S, Maruno M, et al. In-vivo Assessment of Extrahepatic Metabolism of Paeoniflorin in Rats: Relevance to Intestinal Floral Metabolism. J Pharm Pharmacol. 2011; 49: 35–39. https://doi.org/10.1111/j.2042-7158.1997.tb06748.x PMID: 9120767
- Takeda S, Isono T, Wakui Y, Matsuzaki Y, Sasaki H, Amagaya S, et al. Absorption and Excretion of Paeoniflorin in Rats. J Pharm Pharmacol. 2011; 47: 1036–1040. https://doi.org/10.1111/j.2042-7158. 1995.tb03293.x PMID: 8932691
- Zhu L, Sun S, Hu Y, Liu Y. Metabolic study of paeoniflorin and total paeony glucosides from Paeoniae Radix Rubra in rats by high-performance liquid chromatography coupled with sequential mass spectrometry. Biomed Chromatogr. 2018; 32: e4141. https://doi.org/10.1002/bmc.4141 PMID: 29148594
- Cao W, Wang X, Li H, Shi X, Fan W, Zhao S, et al. Studies on metabolism of total glucosides of paeony from Paeoniae Radix Alba in rats by UPLC-Q-TOF-MS/MS: Studies on metabolism of total glucosides of paeony. Biomed Chromatogr. 2015; 29: 1769–1779. <u>https://doi.org/10.1002/bmc.3493</u> PMID: 26058364
- 65. Wang L, Phan DDK, Zhang J, Ong P-S, Thuya WL, Soo R, et al. Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development. Oncotarget. 2016; 7: 44790–44802. https://doi.org/10.18632/oncotarget.8316 PMID: 27027349
- Patel M, Mandava NK, Pal D, Mitra AK. Amino acid prodrug of quinidine: An approach to circumvent Pglycoprotein mediated cellular efflux. Int J Pharm. 2014; 464: 196–204. <u>https://doi.org/10.1016/j.</u> ijpharm.2014.01.006 PMID: 24440401
- 67. Ye L, Yang X, Yang Z, Gao S, Yin T, Liu W, et al. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells. Toxicol Lett. 2013; 216: 86–99. <u>https://doi.org/10.1016/j.toxlet.2012.11</u>. 011 PMID: 23200901
- Tu J, Guo Y, Hong W, Fang Y, Han D, Zhang P, et al. The Regulatory Effects of Paeoniflorin and Its Derivative Paeoniflorin-6'-O-Benzene Sulfonate CP-25 on Inflammation and Immune Diseases. Front Pharmacol. 2019;10. https://doi.org/10.3389/fphar.2019.00057 PMID: 30804784
- Moher D, Avey M, Antes G, Altman DG. Erratum: the National Institutes of Health and guidance for reporting preclinical research. BMC Med. 2015;13. https://doi.org/10.1186/s12916-015-0321-8 PMID: 25889769
- 70. Franco A, Malhotra N, Simonovits G. Publication bias in the social sciences: Unlocking the file drawer. Science. 2014; 345: 1502–1505. https://doi.org/10.1126/science.1255484 PMID: 25170047
- 71. Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. BioMed Res Int. 2021;2021. https://doi.org/10.1155/2021/1497449 PMID: 34307650
- 72. Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. J Med Assoc Thail Chotmaihet Thangphaet. 2010;93 Suppl 6: S228-241. PMID: 21280541
- 73. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008; 4: 444–452. https://doi.org/10.1038/ncpendmet0894 PMID: 18607402